<html lang="en" class="pb-page js" data-request-id="94d6dab1c267af0b-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6dab1c267af0b-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/mhOKHEHGBhcnuqAf74o0_bQCw9YkUW-h-nLh2OZCOv57HVsrPAkWLVy06Uof_sADNO2aIge8Y4-5lvNf4XOhbw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6dab1c267af0b-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.7824113574770035"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Treatments in Oncology|Leukemia/Lymphoma">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2201817","title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Leukemia/Lymphoma","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-06-30T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Leukemia/Lymphoma\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2201817","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma","doi":"10.1056/NEJMdo006569","issueDate":"2022-06-30T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Leukemia/Lymphoma","viewType":"Full","specialties":"Hematology/Oncology"},{"type":"Quick Take","title":"Ibrutinib for Untreated Mantle-Cell Lymphoma","doi":"10.1056/NEJMdo006568","issueDate":"2022-06-30T00:00Z","age":"6Months-1990","isFree":"n","topics":"Treatments in Oncology|Leukemia/Lymphoma","viewType":"Full","specialties":"Hematology/Oncology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6dab1c267af0b-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma"><meta name="dc.Creator" content="Michael L. Wang"><meta name="dc.Creator" content="Wojciech Jurczak"><meta name="dc.Creator" content="Mats Jerkeman"><meta name="dc.Creator" content="Judith Trotman"><meta name="dc.Creator" content="Pier L. Zinzani"><meta name="dc.Creator" content="David Belada"><meta name="dc.Creator" content="Carola Boccomini"><meta name="dc.Creator" content="Ian W. Flinn"><meta name="dc.Creator" content="Pratyush Giri"><meta name="dc.Creator" content="Andre Goy"><meta name="dc.Creator" content="Paul A. Hamlin"><meta name="dc.Creator" content="Olivier Hermine"><meta name="dc.Creator" content="José-Ángel Hernández-Rivas"><meta name="dc.Creator" content="Xiaonan Hong"><meta name="dc.Creator" content="Seok Jin Kim"><meta name="dc.Creator" content="David Lewis"><meta name="dc.Creator" content="Yuko Mishima"><meta name="dc.Creator" content="Muhit Özcan"><meta name="dc.Creator" content="Guilherme F. Perini"><meta name="dc.Creator" content="Christopher Pocock"><meta name="dc.Creator" content="Yuqin Song"><meta name="dc.Creator" content="Stephen E. Spurgeon"><meta name="dc.Creator" content="John M. Storring"><meta name="dc.Creator" content="Jan Walewski"><meta name="dc.Creator" content="Jun Zhu"><meta name="dc.Creator" content="Rui Qin"><meta name="dc.Creator" content="Todd Henninger"><meta name="dc.Creator" content="Sanjay Deshpande"><meta name="dc.Creator" content="Angela Howes"><meta name="dc.Creator" content="Steven Le Gouill"><meta name="dc.Creator" content="Martin Dreyling"><meta name="dc.Description" content="Ibrutinib, a Bruton’s tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older pa..."><meta name="Description" content="Ibrutinib, a Bruton’s tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older pa..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-06-30"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2201817"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202206303862609"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2201817">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2201817">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2201817">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma | NEJM">
        <meta property="og:title" content="Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2201817">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/886df89e-7380-447d-a885-20a73385c3b1/nejmoa2201817_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/886df89e-7380-447d-a885-20a73385c3b1/nejmoa2201817_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Ibrutinib, a Bruton’s tyrosine kinase inhibitor, may have clinical benefit when administered
in combination with bendamustine and rituximab and followed by rituximab maintenance
therapy in older pa...">
        <meta name="twitter:description" content="Ibrutinib, a Bruton’s tyrosine kinase inhibitor, may have clinical benefit when administered
in combination with bendamustine and rituximab and followed by rituximab maintenance
therapy in older pa...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2201817">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2201817">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.386.issue-26;article:article:doi\:10.1056/NEJMoa2201817;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2201817" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2201817" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2201817" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2201817" class="inputDoi"><input type="hidden" value="M.L. Wang and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:2482-2494" class="inputCitation"><input type="hidden" value="06-03-2022" class="inputEPubDate"><input type="hidden" value="June 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6dab1c267af0b-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Michael L.</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9748-5486" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9748-5486</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wojciech</span> <span property="familyName">Jurczak</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mats</span> <span property="familyName">Jerkeman</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Judith</span> <span property="familyName">Trotman</span>, <span property="honorificSuffix">F.R.A.C.P.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pier L.</span> <span property="familyName">Zinzani</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Belada</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carola</span> <span property="familyName">Boccomini</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+24</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ian W.</span> <span property="familyName">Flinn</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pratyush</span> <span property="familyName">Giri</span>, <span property="honorificSuffix">F.R.A.C.P.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andre</span> <span property="familyName">Goy</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Paul A.</span> <span property="familyName">Hamlin</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Olivier</span> <span property="familyName">Hermine</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2574-3874" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2574-3874</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">José-Ángel</span> <span property="familyName">Hernández-Rivas</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xiaonan</span> <span property="familyName">Hong</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Seok Jin</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Lewis</span>, <span property="honorificSuffix">F.R.C.Path., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yuko</span> <span property="familyName">Mishima</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Muhit</span> <span property="familyName">Özcan</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Guilherme F.</span> <span property="familyName">Perini</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christopher</span> <span property="familyName">Pocock</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yuqin</span> <span property="familyName">Song</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stephen E.</span> <span property="familyName">Spurgeon</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John M.</span> <span property="familyName">Storring</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jan</span> <span property="familyName">Walewski</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jun</span> <span property="familyName">Zhu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rui</span> <span property="familyName">Qin</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Todd</span> <span property="familyName">Henninger</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sanjay</span> <span property="familyName">Deshpande</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Angela</span> <span property="familyName">Howes</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Steven</span> <span property="familyName">Le Gouill</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Martin</span> <span property="familyName">Dreyling</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the SHINE Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-24</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 3, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">2482</span>-<span property="pageEnd">2494</span></div><div class="doi">DOI: 10.1056/NEJMoa2201817</div><div class="core-enumeration"><a href="/toc/nejm/386/26"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">26</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMichael%2BL.%2BWang%252C%2BWojciech%2BJurczak%252C%2BMats%2BJerkeman%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D26%26contentID%3D10.1056%252FNEJMoa2201817%26title%3DIbrutinib%2Bplus%2BBendamustine%2Band%2BRituximab%2Bin%2BUntreated%2BMantle-Cell%2BLymphoma%26publicationDate%3D06%252F30%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2201817" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMichael%2BL.%2BWang%252C%2BWojciech%2BJurczak%252C%2BMats%2BJerkeman%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D26%26contentID%3D10.1056%252FNEJMoa2201817%26title%3DIbrutinib%2Bplus%2BBendamustine%2Band%2BRituximab%2Bin%2BUntreated%2BMantle-Cell%2BLymphoma%26publicationDate%3D06%252F30%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/ad716eae-3866-4240-b99f-6584dc7fc143/nejmoa2201817.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2201817.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2201817" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2201817" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2201817.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Ibrutinib, a Bruton’s tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We randomly assigned patients 65 years of age or older to receive ibrutinib (560 mg, administered orally once daily until disease progression or unacceptable toxic effects) or placebo, plus six cycles of bendamustine (90 mg per square meter of body-surface area) and rituximab (375 mg per square meter). Patients with an objective response (complete or partial response) received rituximab maintenance therapy, administered every 8 weeks for up to 12 additional doses. The primary end point was progression-free survival as assessed by the investigators. Overall survival and safety were also assessed.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f0.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/886df89e-7380-447d-a885-20a73385c3b1/assets/images/large/nejmoa2201817_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Among 523 patients, 261 were randomly assigned to receive ibrutinib and 262 to receive placebo. At a median follow-up of 84.7 months, the median progression-free survival was 80.6 months in the ibrutinib group and 52.9 months in the placebo group (hazard ratio for disease progression or death, 0.75; 95% confidence interval, 0.59 to 0.96; P=0.01). The percentage of patients with a complete response was 65.5% in the ibrutinib group and 57.6% in the placebo group (P=0.06). Overall survival was similar in the two groups. The incidence of grade 3 or 4 adverse events during treatment was 81.5% in the ibrutinib group and 77.3% in the placebo group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Ibrutinib treatment in combination with standard chemoimmunotherapy significantly prolonged progression-free survival. The safety profile of the combined therapy was consistent with the known profiles of the individual drugs. (Funded by Janssen Research and Development and Pharmacyclics; SHINE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT01776840" target="_blank">NCT01776840</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006568/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/c421ad1f-c6dc-4952-ae5f-27a63170bb59/media/NEJMdo006568_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006568/full/" class="ng-do-media_item-title-link">Ibrutinib for Untreated Mantle-Cell Lymphoma</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 8s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Mantle-cell lymphoma is a subtype of B-cell non-Hodgkin’s lymphoma and is considered to be incurable.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Most patients with mantle-cell lymphoma are older and are unsuitable candidates for aggressive treatment or autologous stem-cell transplantation, a situation that results in unsatisfactory clinical outcomes.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4 r5" id="body-ref-r5" href-manipulated="true">2-5</a></sup> Current guidelines recommend less-aggressive first-line therapy in older patients, such as bendamustine plus rituximab, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), or VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone).<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r8" id="body-ref-r8" href-manipulated="true">6-8</a></sup> Combination therapy with bendamustine and rituximab has become one of the most-used first-line regimens for mantle-cell lymphoma,<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup> given evidence showing longer progression-free survival with this combination than with R-CHOP (35.4 vs. 22.1 months)<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-1" href-manipulated="true" aria-label="Reference 10">10</a></sup> and a better safety profile.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11" id="body-ref-r11" href-manipulated="true">10,11</a></sup> Two independent observational studies<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r12" id="body-ref-r12" href-manipulated="true">9,12</a></sup> showed significantly prolonged progression-free survival or overall survival with the addition of rituximab maintenance therapy after induction therapy with bendamustine and rituximab, in contrast to the results of a prospective randomized trial.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup> The findings of these observational studies are aligned with the benefits that have been observed with rituximab maintenance therapy after R-CHOP.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup></div><div role="paragraph">Single-agent ibrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, has transformed the care of patients with relapsed or refractory mantle-cell lymphoma with its durable activity, particularly when it is used at first relapse.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16 r17" id="body-ref-r17" href-manipulated="true">15-17</a></sup> A phase 1b study involving 17 patients with untreated, relapsed, or refractory mantle-cell lymphoma showed that the addition of ibrutinib to bendamustine and rituximab therapy was safe and efficacious; 76% of the patients had a complete response.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> Here, we report the primary results of the international, randomized, double-blind, phase 3 SHINE trial, in which we evaluated the combination of ibrutinib with bendamustine plus rituximab and rituximab maintenance therapy, as compared with placebo with bendamustine plus rituximab and rituximab maintenance therapy, in older patients with untreated mantle-cell lymphoma.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">We enrolled eligible patients 65 years of age or older who had a centrally confirmed diagnosis of mantle-cell lymphoma with cyclin C1 overexpression or translocation breakpoints at t(11;14); previously untreated, documented stage II to IV disease; at least one measurable site of disease that was at least 1.5 cm in the longest diameter; an Eastern Cooperative Oncology Group performance-status score of 0 or 1 (on a scale ranging from 0 to 5, with higher numbers indicating greater disability); and adequate organ function. Patients were excluded if stem-cell transplantation was planned or if they had known central nervous system involvement, had a history of stroke or intracranial hemorrhage within 6 months before randomization, were receiving anticoagulation with warfarin or equivalent vitamin K antagonists or treatment with strong CYP3A inhibitors, or had had clinically significant cardiovascular disease within 6 months before screening. Complete eligibility criteria are provided in the trial <a href="#ap1">protocol</a>, which is available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Design and Treatments</h3><div role="paragraph">Randomization was stratified according to the simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score category (low risk [score, 0 to 3], intermediate risk [4 or 5], or high risk [6 to 11]).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-1" href-manipulated="true" aria-label="Reference 19">19</a></sup> Patients were randomly assigned in a 1:1 ratio to receive either ibrutinib, at a dose of 560 mg administered orally once daily, or matching placebo. Ibrutinib or placebo was administered in combination with bendamustine, at a dose of 90 mg per square meter of body-surface area (on days 1 and 2 of each cycle, which was defined as 28 days), and rituximab, at a dose of 375 mg per square meter (on day 1 of each cycle), which were administered every 4 weeks for six cycles. After induction treatment, patients with an objective response (defined as a complete or partial response) continued to receive ibrutinib or placebo daily plus rituximab maintenance therapy at a dose of 375 mg per square meter, administered every 8 weeks for up to 12 additional doses. Patients with a best response of stable disease after induction treatment could continue to receive ibrutinib or placebo only. Ibrutinib or placebo was administered until the occurrence of progressive disease or unacceptable toxic effects. Supportive care, including the use of prophylactic anti-infective agents, was given at the discretion of the investigator.</div></section><section id="sec-1-3"><h3>End Points and Assessments</h3><div role="paragraph">The primary end point, progression-free survival as assessed by the investigators, was defined as the time from randomization to disease progression or death, whichever occurred first. Disease progression was assessed according to the 2007 Revised Response Criteria for Malignant Lymphoma.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup></div><div role="paragraph">Secondary end points included complete response, the time to next treatment, overall survival, objective response, undetectable minimal residual disease (&lt;5 in 10<sup>4</sup> cells as assessed by flow cytometry in patients with a complete response), and the time to worsening as assessed with the Lymphoma subscale of the Functional Assessment of Cancer Therapy–Lymphoma (FACT-Lym) instrument, which measures disease-related symptoms and concerns.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> Safety was also evaluated.</div><div role="paragraph">Efficacy was assessed by means of computed tomographic scans of the neck, chest, abdomen, pelvis, and any other location where disease was present or by means of magnetic resonance imaging if the sites of disease could not be adequately imaged by computed tomography. Radiologic assessments were performed at screening, every 12 weeks during the first 12 months after the initiation of ibrutinib or placebo, and then every 16 weeks until disease progression. A positron-emission tomographic scan was required for the confirmation of a complete response. In addition, patients with bone marrow involvement at baseline were required to undergo a repeat bone marrow evaluation at the time of complete response, and an endoscopy was required in order to confirm a complete response in patients with known gastrointestinal involvement at baseline. Safety was assessed throughout the trial and up to 30 days after the last dose of ibrutinib or placebo. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.03.</div></section><section id="sec-1-4"><h3>Trial Oversight</h3><div role="paragraph">The trial was designed by representatives of Janssen Research and Development in collaboration with the academic investigators and Pharmacyclics; both companies funded the trial. The trial protocol and all amendments were approved by the appropriate ethics committees at each trial site. The trial was conducted in accordance with the Guidelines on Good Clinical Practice from the International Conference on Harmonisation, the principles of the Declaration of Helsinki, and all other applicable regulations. Before enrollment, all the patients provided written informed consent to participate in the trial.</div><div role="paragraph">All the investigators were responsible for the collection of data, which were analyzed by Janssen Research and Development. An independent data and safety monitoring committee performed regular assessments of the efficacy and safety data. The authors had full access to the data, vouch for the accuracy and completeness of the data, and attest that the trial was conducted in accordance with the protocol and all amendments. All the authors contributed to the writing of the manuscript, representatives of Pharmacyclics reviewed the manuscript, and medical writing assistance was funded by Janssen Research and Development.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We calculated the sample size on the basis of the primary end point, progression-free survival. We estimated that the enrollment of approximately 520 patients would be necessary to observe 265 events of disease progression or death, which would provide the trial with approximately 77% power to detect a 30% lower risk of progression or death in the ibrutinib group than in the placebo group at a one-sided significance level of 0.025. The O’Brien–Fleming boundaries were used for a superiority test of efficacy in two interim analyses and one primary analysis. The significance boundary for superiority in the primary analysis was a P value of less than 0.023. Progression-free survival was estimated with the use of the Kaplan–Meier method. The hazard ratio and associated two-sided 95% confidence interval were calculated by a stratified Cox proportional-hazards model. If the primary end point reached statistical significance, tests of secondary end points were to be performed at a two-sided significance level of 0.05 in a sequential hierarchical manner on the basis of a closed testing procedure.</div><div role="paragraph">Overall survival and the time to next treatment were estimated with the use of the Kaplan–Meier method, and a stratified log-rank test was used to compare the trial groups. For the percentages of patients with a complete response, undetectable minimal residual disease, and an objective response, the between-group differences were assessed with the use of the Cochran–Mantel–Haenszel test.</div><div role="paragraph">All the efficacy end points were analyzed in the intention-to-treat population (defined as all the patients who had undergone randomization), and safety was assessed in all the patients who received at least one dose of ibrutinib or placebo. The full statistical analysis plan is available with the protocol.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients and Treatment</h3><div role="paragraph">From May 2013 through November 2014, a total of 523 patients from 183 trial sites in North America, South America, Europe, and the Asia–Pacific region underwent randomization (261 patients in the ibrutinib group and 262 in the placebo group), and 519 patients received at least one dose of ibrutinib or placebo (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). The median age of the patients was 71 years (range, 65 to 87). The characteristics of the patients at baseline were well balanced in the two groups (<a href="#t1">Table 1</a>). Although the trial participants were generally representative of the global population of patients with newly diagnosed mantle-cell lymphoma, Black patients were underrepresented in this trial in the United States (2% of the U.S. patients in this trial vs. a published incidence of 4%) (Table S1).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/85d3d921-a386-40e6-9a92-4c3b812caec0/assets/images/large/nejmoa2201817_t1.jpg" height="3183" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Ibrutinib Group<br>(N=261)</th><th class="txxr-borders">Placebo Group<br>(N=262)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">71 (65–86)</td><td class="xxxr-borders">71 (65–87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥70 yr — no. (%)</td><td class="xxxx-borders shading">162 (62.1)</td><td class="xxxr-borders shading">154 (58.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥75 yr — no. (%)</td><td class="xxxx-borders">74 (28.4)</td><td class="xxxr-borders">82 (31.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders shading">178 (68.2)</td><td class="xxxr-borders shading">186 (71.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">199 (76.2)</td><td class="xxxr-borders shading">206 (78.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">47 (18.0)</td><td class="xxxr-borders shading">42 (16.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other or multiple</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxr-borders">4 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Not reported</td><td class="xxxx-borders shading">10 (3.8)</td><td class="xxxr-borders shading">9 (3.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median time from initial diagnosis to randomization (range) — mo</td><td class="xxxx-borders">1.4 (0.2–116.1)</td><td class="xxxr-borders">1.5 (0.1–66.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">134 (51.3)</td><td class="xxxr-borders">141 (53.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1 or 2</td><td class="xxxx-borders shading">127 (48.7)</td><td class="xxxr-borders shading">121 (46.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disease stage — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">II</td><td class="xxxx-borders shading">9 (3.4)</td><td class="xxxr-borders shading">14 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">III</td><td class="xxxx-borders">19 (7.3)</td><td class="xxxr-borders">22 (8.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IV</td><td class="xxxx-borders shading">233 (89.3)</td><td class="xxxr-borders shading">226 (86.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Simplified MIPI score category — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Low risk</td><td class="xxxx-borders shading">44 (16.9)</td><td class="xxxr-borders shading">46 (17.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate risk</td><td class="xxxx-borders">124 (47.5)</td><td class="xxxr-borders">129 (49.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High risk</td><td class="xxxx-borders shading">93 (35.6)</td><td class="xxxr-borders shading">87 (33.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Bone marrow involvement — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">198 (75.9)</td><td class="xxxr-borders shading">200 (76.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No</td><td class="xxxx-borders">63 (24.1)</td><td class="xxxr-borders">62 (23.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Histologic features — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Blastoid or pleomorphic</td><td class="xxxx-borders">19 (7.3)</td><td class="xxxr-borders">26 (9.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonblastoid or nonpleomorphic</td><td class="xxxx-borders shading">211 (80.8)</td><td class="xxxr-borders shading">201 (76.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unknown</td><td class="xxxx-borders">31 (11.9)</td><td class="xxxr-borders">35 (13.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Extranodal disease — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Yes</td><td class="xxxx-borders">234 (89.7)</td><td class="xxxr-borders">226 (86.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No</td><td class="xxxx-borders shading">27 (10.3)</td><td class="xxxr-borders shading">36 (13.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Tumor bulk — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;5 cm in largest diameter</td><td class="xxxx-borders shading">165 (63.2)</td><td class="xxxr-borders shading">163 (62.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥5 cm in largest diameter</td><td class="xxxx-borders">95 (36.4)</td><td class="xxxr-borders">98 (37.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><i>TP53</i> status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonmutated</td><td class="xxxx-borders shading">114 (43.7)</td><td class="xxxr-borders shading">105 (40.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mutated</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxr-borders">24 (9.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xbxx-borders shading">121 (46.4)</td><td class="xbxr-borders shading">133 (50.8)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline (Intention-to-Treat Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The intention-to-treat population included all the patients who underwent randomization. All patients in the trial also received bendamustine and rituximab. Randomization was stratified according to the simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score (low vs. intermediate vs. high risk).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-2" href-manipulated="true" aria-label="Reference 19">19</a></sup> Scores range from 0 to 11, with a score of 0 to 3 indicating low risk, a score of 4 or 5 indicating intermediate risk, and a score of 6 or higher indicating high risk. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was determined by the investigators.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers indicating greater disability. A score of 0 indicates that the patient is fully active and able to carry on all predisease performance without restriction, a score of 1 that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, and a score of 2 that the patient is ambulatory and capable of all self-care but is unable to carry out any work activities. Three patients in the placebo group had an ECOG performance-status score of 2 (which was outside the protocol specification). In one case, there was a randomization error and the patient was not treated in the trial. Two patients had a score of 1 at randomization but had a score of 2 on day 1 of the first cycle (baseline).</div></div></div></figcaption></figure></div><div role="paragraph">At the data-cutoff date for the primary analysis (June 30, 2021), the median follow-up among all the patients was 84.7 months (7.1 years; range, 0.1 to 97.5 months). In the ibrutinib group, 209 patients (80.7%) received all six cycles of induction therapy with bendamustine and rituximab, and 206 patients (78.9%) received at least one cycle of rituximab maintenance therapy. In the placebo group, 215 patients (82.7%) received all six cycles of induction therapy with bendamustine and rituximab, and 210 patients (80.2%) received at least one cycle of rituximab maintenance therapy. The median duration of the treatment period was 24.1 months (range, 0.2 to 95.2) with ibrutinib and 34.1 months (range, 0.0 to 97.5) with placebo, with a median relative dose intensity of 95% (range, 20 to 100) and 98% (range, 11 to 100), respectively. A total of 54% of the patients received prophylactic anti-infective agents.</div><div role="paragraph">As of the data-cutoff date, 220 patients (84.3%) in the ibrutinib group and 201 (76.7%) in the placebo group had discontinued all trial treatments. The most common reasons for discontinuation were an adverse event (in 39.5% of the patients in the ibrutinib group and in 24.0% of those in the placebo group), progressive disease or relapse (in 10.7% and 34.7%, respectively), withdrawal of consent (in 13.0% and 8.0%), and death (in 10.0% and 5.7%).</div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">A total of 116 patients (44.4%) in the ibrutinib group and 152 (58.0%) in the placebo group had disease progression or died as of the data-cutoff date. The median progression-free survival as assessed by the investigators was 80.6 months (95% confidence interval [CI], 61.9 to not evaluable) in the ibrutinib group, as compared with 52.9 months (95% CI, 43.7 to 71.0) in the placebo group (stratified hazard ratio for disease progression or death, 0.75; 95% CI, 0.59 to 0.96; P=0.01) (<a href="#f1">Figure 1A</a>). The progression-free survival benefit with ibrutinib was observed across most, but not all, prespecified subgroups (<a href="#f2">Figure 2</a> and S2). In particular, patients with a simplified MIPI score category indicating high risk and those with <i>TP53</i> mutations did not have a clear benefit.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f1.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/bb8ba227-09e7-4808-a440-ea40502fbf61/assets/images/large/nejmoa2201817_f1.jpg" height="2809" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival and Overall Survival (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">The intention-to-treat population included all the patients who underwent randomization. Panel A shows the Kaplan–Meier curves for progression-free survival, which was assessed by the investigators according to the Revised Response Criteria for Malignant Lymphoma. The median progression-free survival was 80.6 months (95% CI, 61.9 to not evaluable) with ibrutinib plus bendamustine and rituximab, as compared with 52.9 months (95% CI, 43.7 to 71.0) with placebo plus bendamustine and rituximab. The significance boundary for superiority was a P value of less than 0.023. Panel B shows the Kaplan–Meier curves for overall survival at a median follow-up of 84.7 months (range, 0.1 to 97.5). There was no significant between-group difference in overall survival. As of the data-cutoff date, the median overall survival had not been reached in either group. Symbols in both panels indicate censored data.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f2.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/fb5ae19a-5497-47cf-acc3-462969d3ad6d/assets/images/large/nejmoa2201817_f2.jpg" height="1977" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Subgroup Analysis of Progression-free Survival (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Progression-free survival was assessed by the investigators according to the Revised Response Criteria for Malignant Lymphoma. Race was determined by the investigators. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers indicating greater disability. A score of 0 indicates that the patient is fully active and able to carry on all predisease performance without restriction, a score of 1 that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, and a score of 2 that the patient is ambulatory and capable of all self-care but is unable to carry out any work activities. Scores on the simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) range from 0 to 11, with a score of 0 to 3 indicating low risk, a score of 4 or 5 indicating intermediate risk, and a score of 6 or higher indicating high risk. Tumor bulk was assessed on the largest diameter.</div></div></figcaption></figure></div><div role="paragraph">A complete response, as assessed by the investigators, was observed in 171 patients (65.5%) in the ibrutinib group and in 151 (57.6%) in the placebo group (P=0.06) (Table S2). The percentage of patients with an objective response was similar in the two groups (89.7% in the ibrutinib group and 88.5% in the placebo group). Undetectable minimal residual disease in peripheral blood or bone marrow was observed in 162 of 261 patients (62.1%) in the ibrutinib group and in 148 of 262 patients (56.5%) in the placebo group.</div><div role="paragraph">As of the data-cutoff date, 104 patients (39.8%) in the ibrutinib group and 107 (40.8%) in the placebo group had died. Overall survival was similar in the two groups (hazard ratio for death, 1.07; 95% CI, 0.81 to 1.40) (<a href="#f1">Figure 1B</a>). Overall survival at 7 years was 55.0% in the ibrutinib group and 56.8% in the placebo group. Causes of death throughout the entire trial period are listed in Table S3. Death due to disease progression occurred in 30 patients (11.5%) in the ibrutinib group and in 54 (20.6%) in the placebo group. Death due to progression or to adverse events during the treatment period was reported in 58 patients (22.2%) in the ibrutinib group and in 70 (26.7%) in the placebo group. During the post-treatment follow-up period, 46 patients (17.6%) in the ibrutinib group and 37 (14.1%) in the placebo group died. A post hoc analysis of cause-specific survival that included only deaths due to disease progression or adverse events during treatment showed a hazard ratio of 0.88 (95% CI, 0.62 to 1.24) (Fig. S3).</div><div role="paragraph">Second-line anticancer therapy was received by 52 patients (19.9%) in the ibrutinib group and by 106 (40.5%) in the placebo group; 6 of the 52 patients (12%) in the ibrutinib group received second-line ibrutinib and 41 of the 106 (39%) in the placebo group received a second-line BTK inhibitor (34 patients were treated with ibrutinib, 4 with acalabrutinib, and 3 with zanubrutinib) (Table S4). Data on the time to the next treatment are reported in Figure S4.</div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">Adverse events of grade 3 or 4 during the treatment period occurred in 81.5% of the patients in the ibrutinib group and in 77.3% of those in the placebo group. The most common grade 3 or 4 adverse events (defined as those that occurred in ≥10% of the patients in either group) were neutropenia (in 47.1% of the patients in the ibrutinib group and in 48.1% of those in the placebo group), pneumonia (in 20.1% and 14.2%, respectively), lymphopenia (in 16.2% and 11.9%), anemia (in 15.4% and 8.8%), thrombocytopenia (in 12.7% and 13.1%), rash (in 12.0% and 1.9%), and leukopenia (in 10.0% and 11.2%) (<a href="#t2">Table 2</a>). Adverse events that occurred during the first 6 months (induction period) and from 6 months onward (maintenance period) are listed in Table S5.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t2.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/3064beda-1048-42cf-9e78-ed37027f229b/assets/images/large/nejmoa2201817_t2.jpg" height="3438" width="1548" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">System Organ Class and Preferred Term</th><th class="xxxx-borders" colspan="2"><span>Ibrutinib Group<br>(N=259)</span></th><th class="xxxx-borders" colspan="2"><span>Placebo Group<br>(N=260)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">259 (100)</td><td class="xxxx-borders shading">211 (81.5)</td><td class="xxxx-borders shading">257 (98.8)</td><td class="xxxx-borders shading">201 (77.3)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Infection or infestation</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">87 (33.6)</td><td class="xxxx-borders shading">52 (20.1)</td><td class="xxxx-borders shading">61 (23.5)</td><td class="xxxx-borders shading">37 (14.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">71 (27.4)</td><td class="xxxx-borders">4 (1.5)</td><td class="xxxx-borders">68 (26.2)</td><td class="xxxx-borders">4 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Bronchitis</td><td class="xxxx-borders shading">38 (14.7)</td><td class="xxxx-borders shading">6 (2.3)</td><td class="xxxx-borders shading">38 (14.6)</td><td class="xxxx-borders shading">6 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders">38 (14.7)</td><td class="xxxx-borders">11 (4.2)</td><td class="xxxx-borders">33 (12.7)</td><td class="xxxx-borders">6 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Sinusitis</td><td class="xxxx-borders shading">28 (10.8)</td><td class="xxxx-borders shading">2 (0.8)</td><td class="xxxx-borders shading">34 (13.1)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Conjunctivitis</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">24 (9.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">28 (10.8)</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Herpes zoster infection</td><td class="xxxx-borders">15 (5.8)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">28 (10.8)</td><td class="xxxx-borders">10 (3.8)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Gastrointestinal disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">120 (46.3)</td><td class="xxxx-borders">18 (6.9)</td><td class="xxxx-borders">96 (36.9)</td><td class="xxxx-borders">10 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">107 (41.3)</td><td class="xxxx-borders shading">6 (2.3)</td><td class="xxxx-borders shading">107 (41.2)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">58 (22.4)</td><td class="xxxx-borders">7 (2.7)</td><td class="xxxx-borders">48 (18.5)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">51 (19.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">68 (26.2)</td><td class="xxxx-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxx-borders">30 (11.5)</td><td class="xxxx-borders">2 (0.8)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">General disorder or administration-site condition</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">95 (36.7)</td><td class="xxxx-borders">5 (1.9)</td><td class="xxxx-borders">83 (31.9)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">79 (30.5)</td><td class="xxxx-borders shading">8 (3.1)</td><td class="xxxx-borders shading">77 (29.6)</td><td class="xxxx-borders shading">6 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders">51 (19.7)</td><td class="xxxx-borders">3 (1.2)</td><td class="xxxx-borders">42 (16.2)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">30 (11.6)</td><td class="xxxx-borders shading">2 (0.8)</td><td class="xxxx-borders shading">25 (9.6)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Chills</td><td class="xxxx-borders">18 (6.9)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">39 (15.0)</td><td class="xxxx-borders">1 (0.4)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Blood or lymphatic system disorder<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">133 (51.4)</td><td class="xxxx-borders">122 (47.1)</td><td class="xxxx-borders">136 (52.3)</td><td class="xxxx-borders">125 (48.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">87 (33.6)</td><td class="xxxx-borders shading">40 (15.4)</td><td class="xxxx-borders shading">64 (24.6)</td><td class="xxxx-borders shading">23 (8.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Thrombocytopenia</td><td class="xxxx-borders">93 (35.9)</td><td class="xxxx-borders">33 (12.7)</td><td class="xxxx-borders">69 (26.5)</td><td class="xxxx-borders">34 (13.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Leukopenia</td><td class="xxxx-borders shading">47 (18.1)</td><td class="xxxx-borders shading">26 (10.0)</td><td class="xxxx-borders shading">44 (16.9)</td><td class="xxxx-borders shading">29 (11.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Lymphopenia</td><td class="xxxx-borders">47 (18.1)</td><td class="xxxx-borders">42 (16.2)</td><td class="xxxx-borders">35 (13.5)</td><td class="xxxx-borders">31 (11.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Skin or subcutaneous tissue disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Rash</td><td class="xxxx-borders">98 (37.8)</td><td class="xxxx-borders">31 (12.0)</td><td class="xxxx-borders">57 (21.9)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">46 (17.8)</td><td class="xxxx-borders shading">6 (2.3)</td><td class="xxxx-borders shading">56 (21.5)</td><td class="xxxx-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Maculopapular rash</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">12 (4.6)</td><td class="xxxx-borders">10 (3.8)</td><td class="xxxx-borders">3 (1.2)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Respiratory, thoracic, or mediastinal disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Cough</td><td class="xxxx-borders">77 (29.7)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">85 (32.7)</td><td class="xxxx-borders">2 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Epistaxis</td><td class="xxxx-borders shading">31 (12.0)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">12 (4.6)</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Dyspnea</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">46 (17.7)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Metabolism or nutrition disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">56 (21.6)</td><td class="xxxx-borders">4 (1.5)</td><td class="xxxx-borders">36 (13.8)</td><td class="xxxx-borders">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders shading">39 (15.1)</td><td class="xxxx-borders shading">19 (7.3)</td><td class="xxxx-borders shading">31 (11.9)</td><td class="xxxx-borders shading">14 (5.4)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Musculoskeletal or connective-tissue disorder</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Arthralgia</td><td class="xxxx-borders shading">45 (17.4)</td><td class="xxxx-borders shading">3 (1.2)</td><td class="xxxx-borders shading">44 (16.9)</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">36 (13.9)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">37 (14.2)</td><td class="xxxx-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Myalgia</td><td class="xxxx-borders shading">31 (12.0)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">30 (11.5)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Nervous system disorder: headache</td><td class="xxxx-borders">33 (12.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">40 (15.4)</td><td class="xxxx-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Vascular disorder: hypertension</td><td class="xxxx-borders shading">35 (13.5)</td><td class="xxxx-borders shading">22 (8.5)</td><td class="xxxx-borders shading">29 (11.2)</td><td class="xxxx-borders shading">15 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Injury, poisoning, or procedural complication: infusion-related reaction</td><td class="xxxx-borders">21 (8.1)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">30 (11.5)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Cardiac disorder: atrial fibrillation</td><td class="xxxx-borders shading">36 (13.9)</td><td class="xxxx-borders shading">10 (3.9)</td><td class="xxxx-borders shading">17 (6.5)</td><td class="xxxx-borders shading">2 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Psychiatric disorder: insomnia</td><td class="xxxx-borders">29 (11.2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">28 (10.8)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Investigations: decreased weight</td><td class="xxxx-borders shading">26 (10.0)</td><td class="xxxx-borders shading">3 (1.2)</td><td class="xxxx-borders shading">20 (7.7)</td><td class="xxxx-borders shading">1 (0.4)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events during Treatment That Occurred in at Least 10% of the Patients in Either Group (Safety Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">An adverse event during treatment was defined as any event that occurred after the first dose of ibrutinib or placebo, through the treatment phase, or during the 30 days after the last dose of ibrutinib or placebo or until subsequent anticancer therapy, whichever occurred first; or as any event that was considered by the investigators to be related to ibrutinib or placebo regardless of the start date of the event; or as any event that was present at baseline but that worsened in severity or was subsequently considered by the investigator to be related to ibrutinib or placebo. The safety population included all the patients who received at least one dose of ibrutinib or placebo.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Preferred terms that were reported by the investigators were combined as follows: neutropenia (“neutropenia” and “neutrophil count decreased”), anemia (“anemia” and “hemoglobin decreased”), thrombocytopenia (“thrombocytopenia” and “platelet count decreased”), leukopenia (“leukopenia” and “white-cell count decreased’), and lymphopenia (“lymphopenia” and “lymphocyte count decreased”).</div></div></div></figcaption></figure></div><div role="paragraph">Of the adverse events of clinical interest for BTK inhibitors, atrial fibrillation was reported in 13.9% of the patients in the ibrutinib group and in 6.5% of those in the placebo group; hypertension in 13.5% and 11.2%, respectively; diarrhea in 46.3% and 36.9%; major hemorrhage in 5.8% and 4.2%; and arthralgia in 17.4% and 16.9%. Pneumocystis pneumonia was noted in 1 patient in each group, and aspergillus infection was diagnosed in 4 patients in the ibrutinib group and in 1 patient in the placebo group.</div><div role="paragraph">Adverse events during the treatment period were the primary cause of death in 28 patients (10.7%) in the ibrutinib group and in 16 (6.1%) in the placebo group (<a href="#t3">Table 3</a>). Among these events, death due to cardiac disorders occurred in 3 patients in the ibrutinib group and in 5 in the placebo group. During the entire trial period, second primary cancers were observed in 20.8% of the patients in the ibrutinib group and in 18.8% of those in the placebo group; myelodysplastic syndrome or acute myeloid leukemia was observed in 2 patients in the ibrutinib group and in 3 in the placebo group. There were 5 deaths due to coronavirus disease 2019; of these deaths, 3 in the ibrutinib group occurred during the treatment period, and 2 in the placebo group occurred after the treatment period.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t3.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/c239e748-d800-44ee-a939-565ded8e29cd/assets/images/large/nejmoa2201817_t3.jpg" height="2039" width="1136" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Cause</th><th class="txxx-borders">Ibrutinib Group<br>(N=261)</th><th class="txxr-borders">Placebo Group<br>(N=262)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Adverse event during treatment — no. (%)</td><td class="xxxx-borders shading">28 (10.7)</td><td class="xxxr-borders shading">16 (6.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Infection or infestation, excluding Covid-19 — no.<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">9</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Covid-19–related event — no.</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Unknown cause — no.</td><td class="xxxx-borders">3</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cardiac disorder — no.<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Sudden death — no.</td><td class="xxxx-borders">2</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Multiple organ dysfunction syndrome — no.</td><td class="xxxx-borders shading">2</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Respiratory disorder — no.</td><td class="xxxx-borders">1</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">General physical health deterioration — no.</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Traumatic intracranial hemorrhage — no.</td><td class="xxxx-borders">1</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Tumor lysis syndrome — no.</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Cancer — no.<a href="#t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">1</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Ischemic stroke — no.</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Hemorrhagic stroke — no.</td><td class="xbxx-borders">0</td><td class="xbxr-borders">1</td></tr></tbody></table></div><figcaption><div class="caption">Causes of Death Due to Adverse Events during Treatment.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">An adverse event during treatment was defined as any event that occurred after the first dose of ibrutinib or placebo, through the treatment phase, or during the 30 days after the last dose of ibrutinib or placebo or until subsequent anticancer therapy, whichever occurred first; or as any event that was considered by the investigator to be related to ibrutinib or placebo regardless of the start date of the event; or as any event that was present at baseline but that worsened in severity or was subsequently considered by the investigator to be related to ibrutinib or placebo. Covid-19 denotes coronavirus disease 2019.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Grade 5 events of infections and infestations in the ibrutinib group included pneumonia (in two patients) and bronchopulmonary aspergillosis, hepatitis B virus infection, nosocomial infection, <i>Pneumocystis jirovecii</i> pneumonia, fungal pneumonia, viral pneumonia, and sepsis (in one patient each); events in the placebo group included pneumonia, pulmonary sepsis, sepsis, septic shock, and pseudomembranous colitis (in one patient each).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">Grade 5 events of cardiac disorders in the ibrutinib group included cardiac arrest (in two patients) and cardiorespiratory arrest (in one); events in the placebo group included cardiopulmonary failure (in two patients) and cardiac arrest and myocardial infarction (in one patient each).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">Grade 5 events of cancer occurred in one patient in the ibrutinib group (acute myeloid leukemia) and in two in the placebo group (acute myeloid leukemia and myelodysplastic syndrome).</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Patient-Reported Outcomes</h3><div role="paragraph">No significant between-group difference was observed in the time to worsening as assessed on the Lymphoma subscale of the FACT-Lym instrument (hazard ratio, 1.02; 95% CI, 0.83 to 1.26). Details are provided in Figure S5.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In the SHINE trial, the addition of once-daily ibrutinib treatment to bendamustine plus rituximab and rituximab maintenance therapy led to a significant prolongation of 2.3 years in the median progression-free survival (6.7 years, vs. 4.4 years in the placebo group) among older patients with previously untreated mantle-cell lymphoma. This result was longer than published data with the commonly used regimens of R-CHOP, VR-CAP, or bendamustine plus rituximab alone, for which the median progression-free survival was 1.5 to 3.5 years.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r22 r23 r24" id="body-ref-r24" href-manipulated="true">9,10,22–24</a></sup> The separation of the progression-free survival curves occurred within the first year after the initiation of treatment, and the benefit was durable throughout the median follow-up of 7 years. Patients with a simplified MIPI score category indicating high risk did not have a clear benefit in the ibrutinib group as compared with the placebo group. Blastoid or pleomorphic histologic features or <i>TP53</i> mutation were poor risk factors in both trial groups. These observations will need to be assessed further because the present trial was not powered to compare progression-free survival in these subgroups.</div><div role="paragraph">Among the secondary end points, the higher percentage of patients with a complete response (65.5%) that was observed in the ibrutinib group was not significant. The duration of response was longer in the ibrutinib group than in the placebo group, probably owing to disease control with ongoing ibrutinib treatment after the induction period. Overall survival was similar in the two trial groups, with the total percentage of deaths due to progressive disease or adverse events being slightly lower in the ibrutinib group (22.2% of patients) than in the placebo group (26.7%). Specifically, more deaths were due to adverse events in the ibrutinib group than in the placebo group (in 10.7% vs. 6.1% of the patients), and more deaths were due to progressive mantle-cell lymphoma in the placebo group (11.5% of the patients in the ibrutinib group vs. 20.6% of those in the placebo group). The incidence of death from competing risks that occurred during the post-treatment follow-up period was slightly higher in the ibrutinib group than in the placebo group (17.6% and 14.1%, respectively). No clear patterns were noted among the causes of death in either trial group in this older population of patients with a median age of 71 years. The findings in the analysis of overall survival may also have been influenced by the use of subsequent antilymphoma therapies.</div><div role="paragraph">This trial was not designed to answer the question of whether first-line combination therapy with ibrutinib, bendamustine, and rituximab would be superior to the receipt of ibrutinib therapy after bendamustine and rituximab treatment. Given the shorter progression-free survival with current standard-care chemoimmunotherapy options, a prolongation of progression-free survival in response to primary therapy may provide patients with an improved opportunity for durable disease control in order to prevent or delay relapse.</div><div role="paragraph">The improved efficacy with the addition of ibrutinib was accompanied by additional toxic effects. The adverse events were consistent with the known profiles of single-agent ibrutinib, bendamustine, and rituximab.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r16" id="body-ref-r16-2" href-manipulated="true">10,16</a></sup> The incidence of infections, particularly pneumonia, was similar in the two trial groups during the first 6 months but was higher in the ibrutinib group than in the placebo group during the maintenance period. In rare cases, infections were fatal, which suggests the continued need for vigilance in identifying and managing these adverse events. Strategies may include early detection of and therapy for infections, adequate prophylaxis, and monitoring of immunoglobulin levels during both induction and maintenance therapy. The omission of chemotherapy in ibrutinib combinations may also reduce the risk of serious infections.</div><div role="paragraph">The incidence of atrial fibrillation, an expected adverse event with BTK inhibitors, was higher in the ibrutinib group (13.9%) than in the placebo group (6.5%). Hypertension, arthralgia, and major hemorrhage were observed at similar incidences in the two trial groups over the prolonged follow-up. Overall, despite more adverse events and related discontinuations in the ibrutinib group than in the placebo group, the finding that patient-reported outcomes were similar in the two groups supports an acceptable safety profile of the trial combination. Given that the significant progression-free survival benefit at a median of 6.7 years was observed at a median of 2 years of ibrutinib treatment, continuous treatment with ibrutinib may not be necessary. One hypothesis for further exploration could be the time-limited use of ibrutinib to retain efficacy but avoid ongoing toxic effects and costs associated with continuous treatment.</div><div role="paragraph">Two other covalent BTK inhibitors (acalabrutinib and zanubrutinib) have been approved for the treatment of relapsed mantle-cell lymphoma on the basis of single-group studies in several countries; however, data comparing these agents in patients with mantle-cell lymphoma are limited. Two ongoing trials, ECHO (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02972840" target="_blank">NCT02972840</a>) and MANGROVE (<a href="http://clinicaltrials.gov/show/NCT04002297" target="_blank">NCT04002297</a>), are evaluating the clinical profile of these drugs when they are used continuously as first-line treatment. Several other randomized trials are ongoing and have the potential to address additional questions regarding the first-line use of BTK inhibitors, including the evaluation of a chemotherapy-free combination of ibrutinib and rituximab in older patients (ENRICH; Cancer Research U.K. trial number, <a href="https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-ibrutinib-for-older-people-with-mantle-cell-lymphoma-enrich" target="_blank">CRUK/14/026</a>); time-limited combination therapy with ibrutinib, venetoclax, and rituximab (OASIS-2; <a href="http://clinicaltrials.gov/show/NCT04802590" target="_blank">NCT04802590</a>); and BTK inhibitor combinations in younger patients (TRIANGLE [<a href="http://clinicaltrials.gov/show/NCT02858258" target="_blank">NCT02858258</a>] and EA4181 [<a href="http://clinicaltrials.gov/show/NCT04115631" target="_blank">NCT04115631</a>]).</div><div role="paragraph">The phase 3 SHINE trial showed that ibrutinib in combination with bendamustine plus rituximab and rituximab maintenance therapy was an effective first-line treatment in patients with mantle-cell lymphoma who were 65 years of age or older and were considered to be unsuitable candidates for autologous stem-cell transplantation.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on June 3, 2022, and updated on June 3, 2022, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Janssen Research and Development</span> and Pharmacyclics.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients who participated in this trial and their families; all the personnel at the 183 trial sites in North America, South America, Europe, and the Asia–Pacific region, including the European MCL network and the LYSA group, who cared for the patients and coordinated with Janssen Research and Development to make this trial possible; Leo I. Gordon, M.D., and Simon Rule, M.D., for contributions to the trial design; the members of the independent data and safety monitoring committee (see the <a href="#ap2">Supplementary Appendix</a>); Jenna D. Goldberg, M.D., Chris Enny, B.S., Steven Sun, Ph.D., Shonda Little, M.P.H., Anne Connor, B.S., Jessica Vermeulen, M.D., Ph.D., and Michelle Mahoney, M.S., M.B.A., of Janssen Research and Development, for contributions to the trial design and conduct; and Ward A. Pedersen, Ph.D., of Parexel, for medical writing assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2201817_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2201817/suppl_file/nejmoa2201817_research-summary.pdf" download="nejmoa2201817_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2201817_research-summary.pdf" data-doi="10.1056/NEJMoa2201817">Download</a></li><li>196.21 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2201817_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2201817/suppl_file/nejmoa2201817_protocol.pdf" download="nejmoa2201817_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2201817_protocol.pdf" data-doi="10.1056/NEJMoa2201817">Download</a></li><li>4.78 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2201817_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2201817/suppl_file/nejmoa2201817_appendix.pdf" download="nejmoa2201817_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2201817_appendix.pdf" data-doi="10.1056/NEJMoa2201817">Download</a></li><li>457.21 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2201817_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2201817/suppl_file/nejmoa2201817_disclosures.pdf" download="nejmoa2201817_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2201817_disclosures.pdf" data-doi="10.1056/NEJMoa2201817">Download</a></li><li>1.27 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2201817_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2201817/suppl_file/nejmoa2201817_data-sharing.pdf" download="nejmoa2201817_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2201817_data-sharing.pdf" data-doi="10.1056/NEJMoa2201817">Download</a></li><li>71.34 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. <em>Am J Hematol</em> 2019;94:710-725.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25487" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30963600/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000467587800024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mantle+cell+lymphoma%3A+2019+update+on+the+diagnosis%2C+pathogenesis%2C+prognostication%2C+and+management.&amp;publication_year=2019&amp;journal=Am+J+Hematol&amp;pages=710-725&amp;doi=10.1002%2Fajh.25487&amp;pmid=30963600" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <em>Lancet</em> 2016;388:565-575.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00739-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27313086/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380756600029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Addition+of+high-dose+cytarabine+to+immunochemotherapy+before+autologous+stem-cell+transplantation+in+patients+aged+65+years+or+younger+with+mantle+cell+lymphoma+%28MCL+Younger%29%3A+a+randomised%2C+open-label%2C+phase+3+trial+of+the+European+Mantle+Cell+Lymphoma+Network.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=565-575&amp;doi=10.1016%2FS0140-6736%2816%2900739-X&amp;pmid=27313086" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. <em>N Engl J Med</em> 2017;377:1250-1260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2201817&amp;key=10.1056%2FNEJMoa1701769&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28953447/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411838100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+after+autologous+stem-cell+transplantation+in+mantle-cell+lymphoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1250-1260&amp;doi=10.1056%2FNEJMoa1701769&amp;pmid=28953447" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Robak T, Smolewski P, Robak P, Dreyling M. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <em>Leuk Lymphoma</em> 2019;60:2622-2634.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/10428194.2019.1605511" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31018735/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000470604700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mantle+cell+lymphoma%3A+therapeutic+options+in+transplant-ineligible+patients.&amp;publication_year=2019&amp;journal=Leuk+Lymphoma&amp;pages=2622-2634&amp;doi=10.1080%2F10428194.2019.1605511&amp;pmid=31018735" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Monga N, Tam C, Garside J, et al. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review. <em>Crit Rev Oncol Hematol</em> 2021;158:103212-103212.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.critrevonc.2020.103212" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33383209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000624896000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+efficacy+and+safety+of+first-line+treatments+in+patients+with+mantle+cell+lymphoma%3A+a+systematic+literature+review.&amp;publication_year=2021&amp;journal=Crit+Rev+Oncol+Hematol&amp;pages=103212-103212&amp;doi=10.1016%2Fj.critrevonc.2020.103212&amp;pmid=33383209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. <em>Br J Haematol</em> 2018;182:46-62.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.15283" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29767454/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436244700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guideline+for+the+management+of+mantle+cell+lymphoma.&amp;publication_year=2018&amp;journal=Br+J+Haematol&amp;pages=46-62&amp;doi=10.1111%2Fbjh.15283&amp;pmid=29767454" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em> 2017;28:Suppl_4:iv62-iv71.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdx223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28881919/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405408400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Newly+diagnosed+and+relapsed+mantle+cell+lymphoma%3A+ESMO+clinical+practice+guidelines+for+diagnosis%2C+treatment+and+follow-up.&amp;publication_year=2017&amp;journal=Ann+Oncol&amp;pages=iv62-iv71&amp;doi=10.1093%2Fannonc%2Fmdx223&amp;pmid=28881919" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network (NCCN). <em>Clinical practice guidelines in oncology: B-cell lymphomas, version 5</em>. 2021 (<a href="https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1480">https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1480</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+practice+guidelines+in+oncology%3A+B-cell+lymphomas%2C+version+5&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Martin P, Wang M, Kumar A, et al. Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice. <em>J Clin Oncol</em> 2021;39:Suppl:7504-7504. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2021.39.15_suppl.7504" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000708120604101" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Real-world+%28RW%29+treatment+%28tx%29+patterns+and+outcomes+of+3%2C455+previously+untreated+mantle+cell+lymphoma+%28MCL%29+patients+%28pts%29+in+U.S.+routine+clinical+practice.&amp;publication_year=2021&amp;journal=J+Clin+Oncol&amp;pages=7504-7504&amp;doi=10.1200%2FJCO.2021.39.15_suppl.7504" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] regimens for mantle-cell lymphoma, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Two independent observational studies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] survival was 1.5 to 3.5 years. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. <em>Lancet</em> 2013;381:1203-1210.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(12)61763-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23433739/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317350100030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bendamustine+plus+rituximab+versus+CHOP+plus+rituximab+as+first-line+treatment+for+patients+with+indolent+and+mantle-cell+lymphomas%3A+an+open-label%2C+multicentre%2C+randomised%2C+phase+3+non-inferiority+trial.&amp;publication_year=2013&amp;journal=Lancet&amp;pages=1203-1210&amp;doi=10.1016%2FS0140-6736%2812%2961763-2&amp;pmid=23433739" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] than with R-CHOP (35.4 vs. 22.1 months) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and a better safety profile. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] survival was 1.5 to 3.5 years. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] ibrutinib, bendamustine, and rituximab. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. <em>J Clin Oncol</em> 2019;37:984-991.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.00605" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30811293/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000466717700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+treatment+of+patients+with+indolent+non-Hodgkin+lymphoma+or+mantle-cell+lymphoma+with+bendamustine+plus+rituximab+versus+R-CHOP+or+R-CVP%3A+results+of+the+BRIGHT+5-year+follow-up+study.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=984-991&amp;doi=10.1200%2FJCO.18.00605&amp;pmid=30811293" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Hill BT, Switchenko JM, Martin P, et al. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab (BR). <em>Hematol Oncol</em> 2019;37:Suppl 2:405-407.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hon.75_2631" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+rituximab+is+associated+with+improved+overall+survival+in+mantle+cell+lymphoma+patients+responding+to+induction+therapy+with+bendamustine+%2B+rituximab+%28BR%29.&amp;publication_year=2019&amp;journal=Hematol+Oncol&amp;pages=405-407&amp;doi=10.1002%2Fhon.75_2631" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). <em>J Clin Oncol</em> 2016;34:Suppl:7503-7503. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.34.15_suppl.7503" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404711505017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two+years+rituximab+maintenance+vs.+observation+after+first-line+treatment+with+bendamustine+plus+rituximab+%28B-R%29+in+patients+with+mantle+cell+lymphoma%3A+first+results+of+a+prospective%2C+randomized%2C+multicenter+phase+II+study+%28a+subgroup+study+of+the+StiL+NHL7-2008+MAINTAIN+trial%29.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=7503-7503&amp;doi=10.1200%2FJCO.2016.34.15_suppl.7503" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial. <em>J Clin Oncol</em> 2020;38:248-256.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.01294" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31804876/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508197300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+older+patients+with+mantle+cell+lymphoma+%28MCL%29%3A+long-term+follow-up+of+the+randomized+European+MCL+Elderly+trial.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=248-256&amp;doi=10.1200%2FJCO.19.01294&amp;pmid=31804876" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <em>N Engl J Med</em> 2013;369:507-516.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2201817&amp;key=10.1056%2FNEJMoa1306220&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23782157/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322842000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+BTK+with+ibrutinib+in+relapsed+or+refractory+mantle-cell+lymphoma.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=507-516&amp;doi=10.1056%2FNEJMoa1306220&amp;pmid=23782157" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <em>Leukemia</em> 2018;32:1799-1803.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0023-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29572505/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000441284000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ibrutinib+versus+temsirolimus%3A+3-year+follow-up+of+patients+with+previously+treated+mantle+cell+lymphoma+from+the+phase+3%2C+international%2C+randomized%2C+open-label+RAY+study.&amp;publication_year=2018&amp;journal=Leukemia&amp;pages=1799-1803&amp;doi=10.1038%2Fs41375-018-0023-2&amp;pmid=29572505" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] when it is used at first relapse. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] ibrutinib, bendamustine, and rituximab. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Rule S, Dreyling MH, Goy A, et al. Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. <em>Blood</em> 2019;134:Suppl 1:1538-1538. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2019-124691" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577160402091" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+outcomes+with+ibrutinib+versus+the+prior+regimen%3A+a+pooled+analysis+in+relapsed%2Frefractory+%28R%2FR%29+mantle+cell+lymphoma+%28MCL%29+with+up+to+7.5+years+of+extended+follow-up.&amp;publication_year=2019&amp;journal=Blood&amp;pages=1538-1538&amp;doi=10.1182%2Fblood-2019-124691" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. <em>Blood</em> 2015;125:242-248.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-08-597914" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25355819/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350810200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+1%2F1b+study+of+rituximab%2C+bendamustine%2C+and+ibrutinib+in+patients+with+untreated+and+relapsed%2Frefractory+non-Hodgkin+lymphoma.&amp;publication_year=2015&amp;journal=Blood&amp;pages=242-248&amp;doi=10.1182%2Fblood-2014-08-597914&amp;pmid=25355819" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <em>Blood</em> 2008;111:558-565.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2007-06-095331" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17962512/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000252458700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+new+prognostic+index+%28MIPI%29+for+patients+with+advanced-stage+mantle+cell+lymphoma.&amp;publication_year=2008&amp;journal=Blood&amp;pages=558-565&amp;doi=10.1182%2Fblood-2007-06-095331&amp;pmid=17962512" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] risk [4 or 5], or high risk [6 to 11]). </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r19-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] score (low vs. intermediate vs. high risk). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. <em>J Clin Oncol</em> 2007;25:579-586.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2006.09.2403" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17242396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244176000018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+response+criteria+for+malignant+lymphoma.&amp;publication_year=2007&amp;journal=J+Clin+Oncol&amp;pages=579-586&amp;doi=10.1200%2FJCO.2006.09.2403&amp;pmid=17242396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Hlubocky FJ, Webster K, Cashy J, Beaumont J, Cella D. The development and validation of a measure of health-related quality of life for non-Hodgkin’s lymphoma: the Functional Assessment of Cancer Therapy — Lymphoma (FACT-Lym). <em>Lymphoma</em> 2013;1-9 (<a href="https://www.hindawi.com/journals/lymph/2013/147176/">https://www.hindawi.com/journals/lymph/2013/147176/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1155/2013/147176" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+development+and+validation+of+a+measure+of+health-related+quality+of+life+for+non-Hodgkin%E2%80%99s+lymphoma%3A+the+Functional+Assessment+of+Cancer+Therapy+%E2%80%94+Lymphoma+%28FACT-Lym%29.&amp;publication_year=2013&amp;journal=Lymphoma&amp;pages=1-9&amp;doi=10.1155%2F2013%2F147176" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. <em>N Engl J Med</em> 2015;372:944-953.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2201817&amp;key=10.1056%2FNEJMoa1412096&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25738670/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350304500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bortezomib-based+therapy+for+newly+diagnosed+mantle-cell+lymphoma.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=944-953&amp;doi=10.1056%2FNEJMoa1412096&amp;pmid=25738670" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <em>Lancet Oncol</em> 2018;19:1449-1458.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(18)30685-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30348538/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449100300042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Frontline+bortezomib%2C+rituximab%2C+cyclophosphamide%2C+doxorubicin%2C+and+prednisone+%28VR-CAP%29+versus+rituximab%2C+cyclophosphamide%2C+doxorubicin%2C+vincristine%2C+and+prednisone+%28R-CHOP%29+in+transplantation-ineligible+patients+with+newly+diagnosed+mantle+cell+lymphoma%3A+final+overall+survival+results+of+a+randomised%2C+open-label%2C+phase+3+study.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=1449-1458&amp;doi=10.1016%2FS1470-2045%2818%2930685-5&amp;pmid=30348538" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Albertsson-Lindblad A, Palsdottir T, Smedby KE, Weibull CE, Glimelius I, Jerkeman M. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen — a real world study on patients diagnosed in Sweden 2007–2017. <em>Haematologica</em> 2022;107:740-743.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3324/haematol.2021.279037" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34788983/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000811240400054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+in+mantle+cell+lymphoma+after+frontline+treatment+with+R-bendamustine%2C+R-CHOP+and+the+Nordic+MCL2+regimen+%E2%80%94+a+real+world+study+on+patients+diagnosed+in+Sweden+2007%E2%80%932017.&amp;publication_year=2022&amp;journal=Haematologica&amp;pages=740-743&amp;doi=10.3324%2Fhaematol.2021.279037&amp;pmid=34788983" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/26"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">26</span></span> • <span property="datePublished">June 30, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2482</span>-<span property="pageEnd">2494</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 3, 2022</div><div><b class="core-label">Published in issue</b>: June 30, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/leukemia-lymphoma" alt="View article keyword Leukemia/Lymphoma" data-interactiontype="article_recirculation_click">Leukemia/Lymphoma</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Michael L.</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9748-5486" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9748-5486</a></span>, <span property="author" typeof="Person"><span property="givenName">Wojciech</span> <span property="familyName">Jurczak</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mats</span> <span property="familyName">Jerkeman</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Judith</span> <span property="familyName">Trotman</span>, <span property="honorificSuffix">F.R.A.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pier L.</span> <span property="familyName">Zinzani</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Belada</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carola</span> <span property="familyName">Boccomini</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ian W.</span> <span property="familyName">Flinn</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pratyush</span> <span property="familyName">Giri</span>, <span property="honorificSuffix">F.R.A.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andre</span> <span property="familyName">Goy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Paul A.</span> <span property="familyName">Hamlin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Olivier</span> <span property="familyName">Hermine</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-2574-3874" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-2574-3874</a></span>, <span property="author" typeof="Person"><span property="givenName">José-Ángel</span> <span property="familyName">Hernández-Rivas</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xiaonan</span> <span property="familyName">Hong</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Seok Jin</span> <span property="familyName">Kim</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Lewis</span>, <span property="honorificSuffix">F.R.C.Path., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yuko</span> <span property="familyName">Mishima</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Muhit</span> <span property="familyName">Özcan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Guilherme F.</span> <span property="familyName">Perini</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christopher</span> <span property="familyName">Pocock</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yuqin</span> <span property="familyName">Song</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stephen E.</span> <span property="familyName">Spurgeon</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John M.</span> <span property="familyName">Storring</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jan</span> <span property="familyName">Walewski</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jun</span> <span property="familyName">Zhu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rui</span> <span property="familyName">Qin</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Todd</span> <span property="familyName">Henninger</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sanjay</span> <span property="familyName">Deshpande</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Angela</span> <span property="familyName">Howes</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Steven</span> <span property="familyName">Le Gouill</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Martin</span> <span property="familyName">Dreyling</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the SHINE Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the University of Texas M.D. Anderson Cancer Center, Houston (M.L.W.); Maria Sklodowska-Curie National Research Institute of Oncology, Kraków (W.J.), and Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw (J.W.) — both in Poland; Skane University Hospital and Lund University, Lund, Sweden (M.J.); Concord Repatriation General Hospital, University of Sydney, Sydney (J.T.), and Royal Adelaide Hospital, Adelaide, SA (P.G.) — both in Australia; IRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna (P.L.Z.), and SC Ematologia, Azienda Ospedaliero–Universitaria Città della Salute e della Scienza di Torino, Turin (C.B.) — both in Italy; the Fourth Department of Internal Medicine–Hematology, Charles University Hospital and Faculty of Medicine, Hradec Králové, Czech Republic (D.B.); Sarah Cannon Research Institute and Tennessee Oncology, Nashville (I.W.F.); John Theurer Cancer Center, Hackensack (A.G.), and Janssen Research and Development, Raritan (R.Q., T.H., S.D., A.H.) — both in New Jersey; Memorial Sloan Kettering Cancer Center, New York (P.A.H.); the Department of Hematology, Hôpital Necker, Assistance Publique–Hôpitaux de Paris and Institut Imagine, Université de Paris, INSERM Unité Mixte de Recherche 1183 (O.H.), and Institut Curie Comprehensive Cancer Center (S.L.G.), Paris, and Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM, Université de Nantes, Nantes (S.L.G.) — all in France; the Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid (J.-Á.H.-R.); Fudan University Shanghai Cancer Center, Shanghai (X.H.), and Key Laboratory of Carcinogenesis and Translational Research, Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing (Y.S., J.Z.) — both in China; the Division of Hematology–Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.J.K.); University Hospitals Plymouth NHS Trust, Plymouth (D.L.), and Kent and Canterbury Hospital, Canterbury (C.P.) — both in the United Kingdom; the Department of Hematology–Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo (Y.M.); Ankara University School of Medicine, Ankara, Turkey (M.Ö.); Hospital Israelita Albert Einstein, São Paulo (G.F.P.); the Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland (S.E.S.); the Research Institute of the McGill University Health Centre, McGill University, Montreal (J.M.S.); and Klinikum der Universität München, Ludwig Maximilian University of Munich, Munich, Germany (M.D.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Wang can be contacted at <a href="mailto:miwang@mdanderson.org">miwang@mdanderson.org</a> or at the University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX 77030.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the SHINE trial investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Le Gouill and Dreyling contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">139</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2201817" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="23c521af-e5ad-8a8c-fa83-779f612d32cb"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177" style="display:inline-block;">
                <img alt="Article has an altmetric score of 712" src="https://badges.altmetric.com/?size=320&amp;score=712&amp;types=mmbvttf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_23c521af-e5ad-8a8c-fa83-779f612d32cb" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177&amp;tab=news">
          Picked up by <b>90</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177&amp;tab=twitter">
          Posted by <b>102</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=129217177&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>120</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6dab1c267af0b-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2201817"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-26%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2201817%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="139" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dimitrios Filioglou, </li><li class="list-inline-item cited-by__entry__author">Nina Santa-Cruz, </li><li class="list-inline-item cited-by__entry__author">Geovana S. F. Leite, </li><li class="list-inline-item cited-by__entry__author">Dan W. Davini, </li><li class="list-inline-item cited-by__entry__author">Megan J. Cracchiolo, </li><li class="list-inline-item cited-by__entry__author">Forrest L. Baker, </li><li class="list-inline-item cited-by__entry__author">Muhammad Husnain, </li><li class="list-inline-item cited-by__entry__author">Richard J. Simpson, </li><li class="list-inline-item cited-by__entry__author">Vasilios Voudouris, </li><li class="list-inline-item cited-by__entry__author">Emmanuel Katsanis, </li></ul><span class="cited-by__entry__title">A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo, </span><span class="cited-by__entry__series-title">Cancers, </span><span class="cited-by__entry__volume"><strong>17</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(1889), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/cancers17111889" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/cancers17111889</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/cancers17111889" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ashlyn M. O’LEARY, </li><li class="list-inline-item cited-by__entry__author">Christopher R. D’ANGELO, </li></ul><span class="cited-by__entry__title">Mantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond, </span><span class="cited-by__entry__series-title">Panminerva Medica, </span><span class="cited-by__entry__volume"><strong>67</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.23736/S0031-0808.25.05268-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.23736/S0031-0808.25.05268-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.23736/S0031-0808.25.05268-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Danny Luan, </li><li class="list-inline-item cited-by__entry__author">Neela Easwar, </li><li class="list-inline-item cited-by__entry__author">Zhengming Chen, </li><li class="list-inline-item cited-by__entry__author">Brian Link, </li><li class="list-inline-item cited-by__entry__author">Yucai Wang, </li><li class="list-inline-item cited-by__entry__author">Matthew Maurer, </li><li class="list-inline-item cited-by__entry__author">Brad Kahl, </li><li class="list-inline-item cited-by__entry__author">Laura Pinheiro, </li><li class="list-inline-item cited-by__entry__author">John Leonard, </li><li class="list-inline-item cited-by__entry__author">Peter Martin, </li></ul><span class="cited-by__entry__title">Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy, </span><span class="cited-by__entry__series-title">Clinical Lymphoma Myeloma and Leukemia, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(e383-e392.e1), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clml.2025.01.008" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clml.2025.01.008</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clml.2025.01.008" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alexey V. Danilov, </li><li class="list-inline-item cited-by__entry__author">Craig Sauter, </li><li class="list-inline-item cited-by__entry__author">Tycel Phillips, </li><li class="list-inline-item cited-by__entry__author">Catherine C. Coombs, </li><li class="list-inline-item cited-by__entry__author">Andrew Ip, </li><li class="list-inline-item cited-by__entry__author">Yucai Wang, </li><li class="list-inline-item cited-by__entry__author">Joanna Rhodes, </li><li class="list-inline-item cited-by__entry__author">Lori Leslie, </li><li class="list-inline-item cited-by__entry__author">Jacqueline Barrientos, </li><li class="list-inline-item cited-by__entry__author">Hayder Saeed, </li><li class="list-inline-item cited-by__entry__author">Paolo Strati, </li><li class="list-inline-item cited-by__entry__author">Stefan K. Barta, </li><li class="list-inline-item cited-by__entry__author">Mazyar Shadman, </li></ul><span class="cited-by__entry__title">Perspectives on Current Challenges and Emerging Approaches for Lymphoma Management From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference, </span><span class="cited-by__entry__series-title">Clinical Lymphoma Myeloma and Leukemia, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(e366-e373), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.clml.2025.01.005" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.clml.2025.01.005</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.clml.2025.01.005" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Paul J Bröckelmann, </li><li class="list-inline-item cited-by__entry__author">Edward R Scheffer Cliff, </li><li class="list-inline-item cited-by__entry__author">Gloria Iacoboni, </li><li class="list-inline-item cited-by__entry__author">Florian Simon, </li><li class="list-inline-item cited-by__entry__author">Mary M Horowitz, </li><li class="list-inline-item cited-by__entry__author">Armand Keating, </li><li class="list-inline-item cited-by__entry__author">Maria-Victoria Mateos, </li><li class="list-inline-item cited-by__entry__author">Mohamad Mohty, </li><li class="list-inline-item cited-by__entry__author">Surbhi Sidana, </li><li class="list-inline-item cited-by__entry__author">Yuqin Song, </li><li class="list-inline-item cited-by__entry__author">John R Wingard, </li><li class="list-inline-item cited-by__entry__author">Gita Thanarajasingam, </li></ul><span class="cited-by__entry__title">Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies, </span><span class="cited-by__entry__series-title">The Lancet Haematology, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(e470-e481), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S2352-3026(25)00051-1" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S2352-3026(25)00051-1</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S2352-3026(25)00051-1" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Toby A. Eyre, </li><li class="list-inline-item cited-by__entry__author">Chan Y. Cheah, </li><li class="list-inline-item cited-by__entry__author">Clémentine Sarkozy, </li><li class="list-inline-item cited-by__entry__author">Anita Kumar, </li><li class="list-inline-item cited-by__entry__author">Steven Le Gouill, </li></ul><span class="cited-by__entry__title">Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches, </span><span class="cited-by__entry__series-title">Journal of Clinical Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/JCO-25-00146" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/JCO-25-00146</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/JCO-25-00146" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michael Wang, </li><li class="list-inline-item cited-by__entry__author">David Salek, </li><li class="list-inline-item cited-by__entry__author">David Belada, </li><li class="list-inline-item cited-by__entry__author">Yuqin Song, </li><li class="list-inline-item cited-by__entry__author">Wojciech Jurczak, </li><li class="list-inline-item cited-by__entry__author">Brad S. Kahl, </li><li class="list-inline-item cited-by__entry__author">Jonas Paludo, </li><li class="list-inline-item cited-by__entry__author">Michael P. Chu, </li><li class="list-inline-item cited-by__entry__author">Iryna Kryachok, </li><li class="list-inline-item cited-by__entry__author">Laura Fogliatto, </li><li class="list-inline-item cited-by__entry__author">Chan Y. Cheah, </li><li class="list-inline-item cited-by__entry__author">Marta Morawska, </li><li class="list-inline-item cited-by__entry__author">Juan-Manuel Sancho, </li><li class="list-inline-item cited-by__entry__author">Yufu Li, </li><li class="list-inline-item cited-by__entry__author">Caterina Patti, </li><li class="list-inline-item cited-by__entry__author">Cecily Forsyth, </li><li class="list-inline-item cited-by__entry__author">Jingyang Zhang, </li><li class="list-inline-item cited-by__entry__author">Robin Lesley, </li><li class="list-inline-item cited-by__entry__author">Safaa Ramadan, </li><li class="list-inline-item cited-by__entry__author">Simon Rule, </li><li class="list-inline-item cited-by__entry__author">Martin Dreyling, </li><li class="list-inline-item cited-by__entry__author">Nicolas Cazap, </li><li class="list-inline-item cited-by__entry__author">Maria Cecilia Foncuberta, </li><li class="list-inline-item cited-by__entry__author">Gonzalo Garate, </li><li class="list-inline-item cited-by__entry__author">Jarchum Gustavo, </li><li class="list-inline-item cited-by__entry__author">Miguel A Pavlovsky, </li><li class="list-inline-item cited-by__entry__author">Dardo Riveros, </li><li class="list-inline-item cited-by__entry__author">Ross Baker, </li><li class="list-inline-item cited-by__entry__author">Jason Butler, </li><li class="list-inline-item cited-by__entry__author">Paul Cannell, </li><li class="list-inline-item cited-by__entry__author">Chan Cheah, </li><li class="list-inline-item cited-by__entry__author">Tara Cochrane, </li><li class="list-inline-item cited-by__entry__author">Cecily Forsyth, </li><li class="list-inline-item cited-by__entry__author">Pratyush Giri, </li><li class="list-inline-item cited-by__entry__author">Amanda Johnston, </li><li class="list-inline-item cited-by__entry__author">Denise Lee, </li><li class="list-inline-item cited-by__entry__author">Hui-Peng Lee, </li><li class="list-inline-item cited-by__entry__author">Sally Mapp, </li><li class="list-inline-item cited-by__entry__author">Fernando Roncolato, </li><li class="list-inline-item cited-by__entry__author">Aung Thant, </li><li class="list-inline-item cited-by__entry__author">Patricia Walker, </li><li class="list-inline-item cited-by__entry__author">Nicole Wong Doo, </li><li class="list-inline-item cited-by__entry__author">Hilde Demuynck, </li><li class="list-inline-item cited-by__entry__author">Fritz Offner, </li><li class="list-inline-item cited-by__entry__author">Vanessa Van Hende, </li><li class="list-inline-item cited-by__entry__author">Vibeke Vergote, </li><li class="list-inline-item cited-by__entry__author">Ka Lung Wu, </li><li class="list-inline-item cited-by__entry__author">Carlos Chiattone, </li><li class="list-inline-item cited-by__entry__author">Sergio de Azevedo, </li><li class="list-inline-item cited-by__entry__author">Joao Samuel de Holanda Farias, </li><li class="list-inline-item cited-by__entry__author">Laura Fogliatto, </li><li class="list-inline-item cited-by__entry__author">Ana Fonseca, </li><li class="list-inline-item cited-by__entry__author">Nelson Hamerschlak, </li><li class="list-inline-item cited-by__entry__author">Nicolas Lazaretti, </li><li class="list-inline-item cited-by__entry__author">Vanderson Rocha, </li><li class="list-inline-item cited-by__entry__author">Jose Salvador Rodrigues de Oliveira, </li><li class="list-inline-item cited-by__entry__author">Marco Salvino, </li><li class="list-inline-item cited-by__entry__author">Rodrigo Santucci, </li><li class="list-inline-item cited-by__entry__author">Mariza Schaan, </li><li class="list-inline-item cited-by__entry__author">Phillip Scheinberg, </li><li class="list-inline-item cited-by__entry__author">Adriana Scheliga, </li><li class="list-inline-item cited-by__entry__author">Garles Miller Vieira, </li><li class="list-inline-item cited-by__entry__author">Neil Berinstein, </li><li class="list-inline-item cited-by__entry__author">Melina Boutin, </li><li class="list-inline-item cited-by__entry__author">Michael Chu, </li><li class="list-inline-item cited-by__entry__author">Mary-Margaret Keating, </li><li class="list-inline-item cited-by__entry__author">Ariah Schattner, </li><li class="list-inline-item cited-by__entry__author">Diego Villa Restrepo, </li><li class="list-inline-item cited-by__entry__author">Xinan Cen, </li><li class="list-inline-item cited-by__entry__author">Xin Du, </li><li class="list-inline-item cited-by__entry__author">Ru Feng, </li><li class="list-inline-item cited-by__entry__author">Sujun Gao, </li><li class="list-inline-item cited-by__entry__author">Haiwen Huang, </li><li class="list-inline-item cited-by__entry__author">Jie Ji, </li><li class="list-inline-item cited-by__entry__author">Jie Jin, </li><li class="list-inline-item cited-by__entry__author">Xiaoyan Ke, </li><li class="list-inline-item cited-by__entry__author">Dengju Li, </li><li class="list-inline-item cited-by__entry__author">Fei Li, </li><li class="list-inline-item cited-by__entry__author">Jianyong Li, </li><li class="list-inline-item cited-by__entry__author">Junmin Li, </li><li class="list-inline-item cited-by__entry__author">Yan Li, </li><li class="list-inline-item cited-by__entry__author">Yufu Li, </li><li class="list-inline-item cited-by__entry__author">Zhenyu Li, </li><li class="list-inline-item cited-by__entry__author">Li'e Lin, </li><li class="list-inline-item cited-by__entry__author">Tingbo Liu, </li><li class="list-inline-item cited-by__entry__author">Fangfang LV, </li><li class="list-inline-item cited-by__entry__author">Yuerong Shuang, </li><li class="list-inline-item cited-by__entry__author">Yuqin Song, </li><li class="list-inline-item cited-by__entry__author">Lan Sun, </li><li class="list-inline-item cited-by__entry__author">Xiuhua Sun, </li><li class="list-inline-item cited-by__entry__author">Zhao Wang, </li><li class="list-inline-item cited-by__entry__author">Huijing Wu, </li><li class="list-inline-item cited-by__entry__author">Yaming Xi, </li><li class="list-inline-item cited-by__entry__author">Ruixiang Xia, </li><li class="list-inline-item cited-by__entry__author">Hongwei Xue, </li><li class="list-inline-item cited-by__entry__author">Haiyan Yang, </li><li class="list-inline-item cited-by__entry__author">Shuhua Yi, </li><li class="list-inline-item cited-by__entry__author">Cheng Zhang, </li><li class="list-inline-item cited-by__entry__author">Huilai Zhang, </li><li class="list-inline-item cited-by__entry__author">Mingzhi Zhang, </li><li class="list-inline-item cited-by__entry__author">Qingyuan Zhang, </li><li class="list-inline-item cited-by__entry__author">Xielan Zhao, </li><li class="list-inline-item cited-by__entry__author">Hui Zhou, </li><li class="list-inline-item cited-by__entry__author">David Belada, </li><li class="list-inline-item cited-by__entry__author">Roman Hajek, </li><li class="list-inline-item cited-by__entry__author">Pavel Jindra, </li><li class="list-inline-item cited-by__entry__author">Jiri Mayer, </li><li class="list-inline-item cited-by__entry__author">Jan Novak, </li><li class="list-inline-item cited-by__entry__author">Julie Abraham, </li><li class="list-inline-item cited-by__entry__author">Fontanet Bijou, </li><li class="list-inline-item cited-by__entry__author">Kamal Bouabdallah, </li><li class="list-inline-item cited-by__entry__author">Florence Cymbalista, </li><li class="list-inline-item cited-by__entry__author">Sophie de Guilbert, </li><li class="list-inline-item cited-by__entry__author">Vincent Delwail, </li><li class="list-inline-item cited-by__entry__author">Philippe Genet, </li><li class="list-inline-item cited-by__entry__author">Kamel Laribi, </li><li class="list-inline-item cited-by__entry__author">Philippe Rodon, </li><li class="list-inline-item cited-by__entry__author">Thomas Decker, </li><li class="list-inline-item cited-by__entry__author">Peter Dreger, </li><li class="list-inline-item cited-by__entry__author">Martin Dreyling, </li><li class="list-inline-item cited-by__entry__author">Georg Hess, </li><li class="list-inline-item cited-by__entry__author">Georg Lenz, </li><li class="list-inline-item cited-by__entry__author">Stephan Stilgenbauer, </li><li class="list-inline-item cited-by__entry__author">Dirk Tummes, </li><li class="list-inline-item cited-by__entry__author">Konstantinos Anargyrou, </li><li class="list-inline-item cited-by__entry__author">Meletios-Athanassios Dimopoulos, </li><li class="list-inline-item cited-by__entry__author">Eleni Kapsali, </li><li class="list-inline-item cited-by__entry__author">Eirini Katodritou, </li><li class="list-inline-item cited-by__entry__author">Despoina Kyriakou, </li><li class="list-inline-item cited-by__entry__author">Panayiotis Panayiotidis, </li><li class="list-inline-item cited-by__entry__author">Vasiliki Pappa, </li><li class="list-inline-item cited-by__entry__author">Niki Stavroyianni, </li><li class="list-inline-item cited-by__entry__author">Argiris Symeonidis, </li><li class="list-inline-item cited-by__entry__author">Hoi Ching Cheng, </li><li class="list-inline-item cited-by__entry__author">Yok-Lam Kwong, </li><li class="list-inline-item cited-by__entry__author">Harold Lee, </li><li class="list-inline-item cited-by__entry__author">Ting Ying Ng, </li><li class="list-inline-item cited-by__entry__author">Raymond Wong, </li><li class="list-inline-item cited-by__entry__author">Zita Borbenyi, </li><li class="list-inline-item cited-by__entry__author">Árpád Illés, </li><li class="list-inline-item cited-by__entry__author">Zsolt Lazar, </li><li class="list-inline-item cited-by__entry__author">Ágnes Nagy, </li><li class="list-inline-item cited-by__entry__author">Zsolt Nagy, </li><li class="list-inline-item cited-by__entry__author">Tamas Schneider, </li><li class="list-inline-item cited-by__entry__author">Irit Avivi, </li><li class="list-inline-item cited-by__entry__author">Ronit Gurion, </li><li class="list-inline-item cited-by__entry__author">Netanel Horowitz, </li><li class="list-inline-item cited-by__entry__author">Aaron Ronson, </li><li class="list-inline-item cited-by__entry__author">Luca Arcaini, </li><li class="list-inline-item cited-by__entry__author">Carola Boccomini, </li><li class="list-inline-item cited-by__entry__author">Paolo Ghia, </li><li class="list-inline-item cited-by__entry__author">Stefano Luminari, </li><li class="list-inline-item cited-by__entry__author">Caterina Patti, </li><li class="list-inline-item cited-by__entry__author">Caterina Plenteda, </li><li class="list-inline-item cited-by__entry__author">Armando Santoro, </li><li class="list-inline-item cited-by__entry__author">Vittorio Ruggero Zilioli, </li><li class="list-inline-item cited-by__entry__author">Pier Luigi Zinzani, </li><li class="list-inline-item cited-by__entry__author">Ilseung Choi, </li><li class="list-inline-item cited-by__entry__author">Daisuke Ennishi, </li><li class="list-inline-item cited-by__entry__author">Kentaro Fukushima, </li><li class="list-inline-item cited-by__entry__author">Satoshi Ichikawa, </li><li class="list-inline-item cited-by__entry__author">Takayuki Ishikawa, </li><li class="list-inline-item cited-by__entry__author">Koji Izutsu, </li><li class="list-inline-item cited-by__entry__author">Koji Kato, </li><li class="list-inline-item cited-by__entry__author">Dai Maruyama, </li><li class="list-inline-item cited-by__entry__author">Hirokazu Nagai, </li><li class="list-inline-item cited-by__entry__author">Shuichi Ota, </li><li class="list-inline-item cited-by__entry__author">Toko Saito, </li><li class="list-inline-item cited-by__entry__author">Rika Sakai, </li><li class="list-inline-item cited-by__entry__author">Ritsuro Suzuki, </li><li class="list-inline-item cited-by__entry__author">Hiro Tatetsu, </li><li class="list-inline-item cited-by__entry__author">Nobuhiko Uoshima, </li><li class="list-inline-item cited-by__entry__author">Takahiro Yano, </li><li class="list-inline-item cited-by__entry__author">Isao Yoshida, </li><li class="list-inline-item cited-by__entry__author">Ki-Seong Eom, </li><li class="list-inline-item cited-by__entry__author">Jin Seok Kim, </li><li class="list-inline-item cited-by__entry__author">Sang-A Kim, </li><li class="list-inline-item cited-by__entry__author">Seok Jin Kim, </li><li class="list-inline-item cited-by__entry__author">Jung-Hee Lee, </li><li class="list-inline-item cited-by__entry__author">Yeung Chul Mun, </li><li class="list-inline-item cited-by__entry__author">Sung Yong Oh, </li><li class="list-inline-item cited-by__entry__author">Sung Soo Yoon, </li><li class="list-inline-item cited-by__entry__author">Elsa Veronica Avila Arreguin, </li><li class="list-inline-item cited-by__entry__author">Adriana Dominguez Andrade, </li><li class="list-inline-item cited-by__entry__author">David Gomez Almaguer, </li><li class="list-inline-item cited-by__entry__author">Maria Silvia Rivas Vera, </li><li class="list-inline-item cited-by__entry__author">Luis Solis Anaya, </li><li class="list-inline-item cited-by__entry__author">Leanne Berkahn, </li><li class="list-inline-item cited-by__entry__author">Samar Issa, </li><li class="list-inline-item cited-by__entry__author">Lucy Pemberton, </li><li class="list-inline-item cited-by__entry__author">David Simpson, </li><li class="list-inline-item cited-by__entry__author">Brady Beltran, </li><li class="list-inline-item cited-by__entry__author">Shirely Quintana, </li><li class="list-inline-item cited-by__entry__author">Jose Carlos Revilla, </li><li class="list-inline-item cited-by__entry__author">Ernesto Vargas, </li><li class="list-inline-item cited-by__entry__author">Sebastian Grosicki, </li><li class="list-inline-item cited-by__entry__author">Janusz Halka, </li><li class="list-inline-item cited-by__entry__author">Wieslaw Jedrzejczak, </li><li class="list-inline-item cited-by__entry__author">Wojciech Jurczak, </li><li class="list-inline-item cited-by__entry__author">Wanda Knopinska-Posluszny, </li><li class="list-inline-item cited-by__entry__author">Jacek Krzanowski, </li><li class="list-inline-item cited-by__entry__author">Ewa Lech-Maranda, </li><li class="list-inline-item cited-by__entry__author">Marta Morawska, </li><li class="list-inline-item cited-by__entry__author">Tadeusz Robak, </li><li class="list-inline-item cited-by__entry__author">Piotr Rzepecki, </li><li class="list-inline-item cited-by__entry__author">Tomasz Wróbel, </li><li class="list-inline-item cited-by__entry__author">Gabriela Borsaru, </li><li class="list-inline-item cited-by__entry__author">Tudor Eliade Ciuleanu, </li><li class="list-inline-item cited-by__entry__author">Catalin Danaila, </li><li class="list-inline-item cited-by__entry__author">Mihaela Lazaroiu, </li><li class="list-inline-item cited-by__entry__author">Julia Alexeeva, </li><li class="list-inline-item cited-by__entry__author">Valeriy Chistyakov, </li><li class="list-inline-item cited-by__entry__author">Georgy Manikhas, </li><li class="list-inline-item cited-by__entry__author">Natalia Mikhailova, </li><li class="list-inline-item cited-by__entry__author">Andrey Proydakov, </li><li class="list-inline-item cited-by__entry__author">Elena Mikhailovna Volodicheva, </li><li class="list-inline-item cited-by__entry__author">Sergey Voloshin, </li><li class="list-inline-item cited-by__entry__author">Mariana Bastos, </li><li class="list-inline-item cited-by__entry__author">Javier Briones, </li><li class="list-inline-item cited-by__entry__author">Raul Cordoba, </li><li class="list-inline-item cited-by__entry__author">Jose Gómez Codina, </li><li class="list-inline-item cited-by__entry__author">Eva Maria Gonzalez, </li><li class="list-inline-item cited-by__entry__author">Ana Marin, </li><li class="list-inline-item cited-by__entry__author">Carlos Panizo, </li><li class="list-inline-item cited-by__entry__author">Guillermo Rodriguez, </li><li class="list-inline-item cited-by__entry__author">Antonio Salar, </li><li class="list-inline-item cited-by__entry__author">Juan-Manuel Sancho, </li><li class="list-inline-item cited-by__entry__author">Jose A Velo, </li><li class="list-inline-item cited-by__entry__author">Victor Jimenez Yuste, </li><li class="list-inline-item cited-by__entry__author">Chien-Yuan Chen, </li><li class="list-inline-item cited-by__entry__author">Chang-Fang Chiu, </li><li class="list-inline-item cited-by__entry__author">Liang-Tsai Hsiao, </li><li class="list-inline-item cited-by__entry__author">Ching-Yuan Kuo, </li><li class="list-inline-item cited-by__entry__author">Tung-Liang Lin, </li><li class="list-inline-item cited-by__entry__author">Iryna Kryachok, </li><li class="list-inline-item cited-by__entry__author">Tamila Lysa, </li><li class="list-inline-item cited-by__entry__author">Zvenyslava Maslyak, </li><li class="list-inline-item cited-by__entry__author">Larysa Nogaieva, </li><li class="list-inline-item cited-by__entry__author">Sergey Polenkov, </li><li class="list-inline-item cited-by__entry__author">Ganna Usenko, </li><li class="list-inline-item cited-by__entry__author">Richie Agajanian, </li><li class="list-inline-item cited-by__entry__author">Bertrand Anz, </li><li class="list-inline-item cited-by__entry__author">Arvind Chaudhry, </li><li class="list-inline-item cited-by__entry__author">Alden Chiu, </li><li class="list-inline-item cited-by__entry__author">Jennifer Cultrera, </li><li class="list-inline-item cited-by__entry__author">James D'Olimpio, </li><li class="list-inline-item cited-by__entry__author">Kieron Dunleavy, </li><li class="list-inline-item cited-by__entry__author">Suzanne Fanning, </li><li class="list-inline-item cited-by__entry__author">Ian Flinn, </li><li class="list-inline-item cited-by__entry__author">Nashat Gabrail, </li><li class="list-inline-item cited-by__entry__author">David Gallinson, </li><li class="list-inline-item cited-by__entry__author">Alec Goldenberg, </li><li class="list-inline-item cited-by__entry__author">Andre Goy, </li><li class="list-inline-item cited-by__entry__author">Solomon Graf, </li><li class="list-inline-item cited-by__entry__author">Natalie Grover, </li><li class="list-inline-item cited-by__entry__author">Brian Hess, </li><li class="list-inline-item cited-by__entry__author">Marc Hoffman, </li><li class="list-inline-item cited-by__entry__author">Iris Isufi, </li><li class="list-inline-item cited-by__entry__author">Brad Kahl, </li><li class="list-inline-item cited-by__entry__author">Suman Kambhampati, </li><li class="list-inline-item cited-by__entry__author">Dean Kirkel, </li><li class="list-inline-item cited-by__entry__author">Guillermo Lazo Diaz, </li><li class="list-inline-item cited-by__entry__author">Moshe Levy, </li><li class="list-inline-item cited-by__entry__author">Delong Liu, </li><li class="list-inline-item cited-by__entry__author">Monica Mead, </li><li class="list-inline-item cited-by__entry__author">Jonas Paludo, </li><li class="list-inline-item cited-by__entry__author">Anjan Patel, </li><li class="list-inline-item cited-by__entry__author">Shachar Peles, </li><li class="list-inline-item cited-by__entry__author">Daniel Persky, </li><li class="list-inline-item cited-by__entry__author">Craig Portell, </li><li class="list-inline-item cited-by__entry__author">Allison Rosenthal, </li><li class="list-inline-item cited-by__entry__author">Dahlia Sano, </li><li class="list-inline-item cited-by__entry__author">Sonali Smith, </li><li class="list-inline-item cited-by__entry__author">Stephen Smith, </li><li class="list-inline-item cited-by__entry__author">Stephen Spurgeon, </li><li class="list-inline-item cited-by__entry__author">Don Stevens, </li><li class="list-inline-item cited-by__entry__author">Jason Tache, </li><li class="list-inline-item cited-by__entry__author">Michaela Tsai, </li><li class="list-inline-item cited-by__entry__author">Lauren Veltri, </li><li class="list-inline-item cited-by__entry__author">Michael Wang, </li><li class="list-inline-item cited-by__entry__author">Habte Yimer, </li><li class="list-inline-item cited-by__entry__author">Quoc Khanh Bach, </li><li class="list-inline-item cited-by__entry__author">Huyen Nga Do, </li><li class="list-inline-item cited-by__entry__author">Hung Vu Luu, </li><li class="list-inline-item cited-by__entry__author">Trong Khoa Mai, </li><li class="list-inline-item cited-by__entry__author">Nhu Hiep Pham, </li><li class="list-inline-item cited-by__entry__author">Thanh Tung Tran, </li></ul><span class="cited-by__entry__title">Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma, </span><span class="cited-by__entry__series-title">Journal of Clinical Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/JCO-25-00690" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/JCO-25-00690</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/JCO-25-00690" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Clémentine Sarkozy, </li><li class="list-inline-item cited-by__entry__author">Loïc Chartier, </li><li class="list-inline-item cited-by__entry__author">Vincent Ribrag, </li><li class="list-inline-item cited-by__entry__author">Remy Gressin, </li><li class="list-inline-item cited-by__entry__author">Christian H. Geisler, </li><li class="list-inline-item cited-by__entry__author">Hanneke C. Kluin-Nelemans, </li><li class="list-inline-item cited-by__entry__author">Catherine Thieblemont, </li><li class="list-inline-item cited-by__entry__author">Franck Morschhauser, </li><li class="list-inline-item cited-by__entry__author">François Lemonnier, </li><li class="list-inline-item cited-by__entry__author">Violaine Safar, </li><li class="list-inline-item cited-by__entry__author">Benoît Tessoulin, </li><li class="list-inline-item cited-by__entry__author">Lucie Oberic, </li><li class="list-inline-item cited-by__entry__author">Ghandi Damaj, </li><li class="list-inline-item cited-by__entry__author">Hervé Ghesquières, </li><li class="list-inline-item cited-by__entry__author">Krimo Bouabdallah, </li><li class="list-inline-item cited-by__entry__author">René Olivier Casasnovas, </li><li class="list-inline-item cited-by__entry__author">Roch Houot, </li><li class="list-inline-item cited-by__entry__author">Wolfram Klapper, </li><li class="list-inline-item cited-by__entry__author">Barbara Burroni, </li><li class="list-inline-item cited-by__entry__author">Christiane Pott, </li><li class="list-inline-item cited-by__entry__author">Marie-Hélène Delfau-Larue, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Macintyre, </li><li class="list-inline-item cited-by__entry__author">Mary Callanan, </li><li class="list-inline-item cited-by__entry__author">Mats Jerkeman, </li><li class="list-inline-item cited-by__entry__author">Michael Unterhalt, </li><li class="list-inline-item cited-by__entry__author">Eva Hoster, </li><li class="list-inline-item cited-by__entry__author">Martin Dreyling, </li><li class="list-inline-item cited-by__entry__author">Steven Le Gouill, </li><li class="list-inline-item cited-by__entry__author">Olivier Hermine, </li><li class="list-inline-item cited-by__entry__author">Morgane Cheminant, </li></ul><span class="cited-by__entry__title">Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study, </span><span class="cited-by__entry__series-title">Blood Cancer Journal, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41408-025-01241-9" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41408-025-01241-9</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41408-025-01241-9" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Peter Dreger, </li><li class="list-inline-item cited-by__entry__author">Sairah Ahmed, </li><li class="list-inline-item cited-by__entry__author">Ali Bazarbachi, </li><li class="list-inline-item cited-by__entry__author">Sascha Dietrich, </li><li class="list-inline-item cited-by__entry__author">Timothy S. Fenske, </li><li class="list-inline-item cited-by__entry__author">Nilanjan Ghosh, </li><li class="list-inline-item cited-by__entry__author">Olivier Hermine, </li><li class="list-inline-item cited-by__entry__author">Mehdi Hamadani, </li></ul><span class="cited-by__entry__title">How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives, </span><span class="cited-by__entry__series-title">Bone Marrow Transplantation, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41409-025-02599-x" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41409-025-02599-x</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41409-025-02599-x" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ron D. Jachimowicz, </li><li class="list-inline-item cited-by__entry__author">Martin Dreyling, </li></ul><span class="cited-by__entry__title">Stellenwert neuer Therapiemodalitäten beim MantelzelllymphomRole of new treatment modalities in mantel cell lymphoma, </span><span class="cited-by__entry__series-title">Die Onkologie, </span><span class="cited-by__entry__volume"><strong>31</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(578-583), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s00761-025-01710-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s00761-025-01710-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s00761-025-01710-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-26%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2201817%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2201817" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2201817" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2201817.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f0.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/886df89e-7380-447d-a885-20a73385c3b1/assets/images/large/nejmoa2201817_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f1.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/bb8ba227-09e7-4808-a440-ea40502fbf61/assets/images/large/nejmoa2201817_f1.jpg" height="2809" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival and Overall Survival (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">The intention-to-treat population included all the patients who underwent randomization. Panel A shows the Kaplan–Meier curves for progression-free survival, which was assessed by the investigators according to the Revised Response Criteria for Malignant Lymphoma. The median progression-free survival was 80.6 months (95% CI, 61.9 to not evaluable) with ibrutinib plus bendamustine and rituximab, as compared with 52.9 months (95% CI, 43.7 to 71.0) with placebo plus bendamustine and rituximab. The significance boundary for superiority was a P value of less than 0.023. Panel B shows the Kaplan–Meier curves for overall survival at a median follow-up of 84.7 months (range, 0.1 to 97.5). There was no significant between-group difference in overall survival. As of the data-cutoff date, the median overall survival had not been reached in either group. Symbols in both panels indicate censored data.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f2.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/fb5ae19a-5497-47cf-acc3-462969d3ad6d/assets/images/large/nejmoa2201817_f2.jpg" height="1977" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Subgroup Analysis of Progression-free Survival (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Progression-free survival was assessed by the investigators according to the Revised Response Criteria for Malignant Lymphoma. Race was determined by the investigators. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers indicating greater disability. A score of 0 indicates that the patient is fully active and able to carry on all predisease performance without restriction, a score of 1 that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, and a score of 2 that the patient is ambulatory and capable of all self-care but is unable to carry out any work activities. Scores on the simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) range from 0 to 11, with a score of 0 to 3 indicating low risk, a score of 4 or 5 indicating intermediate risk, and a score of 6 or higher indicating high risk. Tumor bulk was assessed on the largest diameter.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2201817/asset/85d3d921-a386-40e6-9a92-4c3b812caec0/assets/images/large/nejmoa2201817_t1.jpg" height="3183" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Ibrutinib Group<br>(N=261)</th><th class="txxr-borders">Placebo Group<br>(N=262)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median (range) — yr</td><td class="xxxx-borders">71 (65–86)</td><td class="xxxr-borders">71 (65–87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥70 yr — no. (%)</td><td class="xxxx-borders shading">162 (62.1)</td><td class="xxxr-borders shading">154 (58.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥75 yr — no. (%)</td><td class="xxxx-borders">74 (28.4)</td><td class="xxxr-borders">82 (31.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders shading">178 (68.2)</td><td class="xxxr-borders shading">186 (71.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">199 (76.2)</td><td class="xxxr-borders shading">206 (78.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">47 (18.0)</td><td class="xxxr-borders shading">42 (16.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other or multiple</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxr-borders">4 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Not reported</td><td class="xxxx-borders shading">10 (3.8)</td><td class="xxxr-borders shading">9 (3.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median time from initial diagnosis to randomization (range) — mo</td><td class="xxxx-borders">1.4 (0.2–116.1)</td><td class="xxxr-borders">1.5 (0.1–66.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ECOG performance-status score — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">0</td><td class="xxxx-borders">134 (51.3)</td><td class="xxxr-borders">141 (53.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">1 or 2</td><td class="xxxx-borders shading">127 (48.7)</td><td class="xxxr-borders shading">121 (46.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Disease stage — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">II</td><td class="xxxx-borders shading">9 (3.4)</td><td class="xxxr-borders shading">14 (5.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">III</td><td class="xxxx-borders">19 (7.3)</td><td class="xxxr-borders">22 (8.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">IV</td><td class="xxxx-borders shading">233 (89.3)</td><td class="xxxr-borders shading">226 (86.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Simplified MIPI score category — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Low risk</td><td class="xxxx-borders shading">44 (16.9)</td><td class="xxxr-borders shading">46 (17.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate risk</td><td class="xxxx-borders">124 (47.5)</td><td class="xxxr-borders">129 (49.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High risk</td><td class="xxxx-borders shading">93 (35.6)</td><td class="xxxr-borders shading">87 (33.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Bone marrow involvement — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">198 (75.9)</td><td class="xxxr-borders shading">200 (76.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No</td><td class="xxxx-borders">63 (24.1)</td><td class="xxxr-borders">62 (23.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Histologic features — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Blastoid or pleomorphic</td><td class="xxxx-borders">19 (7.3)</td><td class="xxxr-borders">26 (9.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonblastoid or nonpleomorphic</td><td class="xxxx-borders shading">211 (80.8)</td><td class="xxxr-borders shading">201 (76.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unknown</td><td class="xxxx-borders">31 (11.9)</td><td class="xxxr-borders">35 (13.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Extranodal disease — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Yes</td><td class="xxxx-borders">234 (89.7)</td><td class="xxxr-borders">226 (86.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">No</td><td class="xxxx-borders shading">27 (10.3)</td><td class="xxxr-borders shading">36 (13.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Tumor bulk — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">&lt;5 cm in largest diameter</td><td class="xxxx-borders shading">165 (63.2)</td><td class="xxxr-borders shading">163 (62.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">≥5 cm in largest diameter</td><td class="xxxx-borders">95 (36.4)</td><td class="xxxr-borders">98 (37.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><i>TP53</i> status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nonmutated</td><td class="xxxx-borders shading">114 (43.7)</td><td class="xxxr-borders shading">105 (40.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mutated</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxr-borders">24 (9.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xbxx-borders shading">121 (46.4)</td><td class="xbxr-borders shading">133 (50.8)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"><div class="label">*</div></a><div id="core-t1fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg">The intention-to-treat population included all the patients who underwent randomization. All patients in the trial also received bendamustine and rituximab. Randomization was stratified according to the simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score (low vs. intermediate vs. high risk).<sup></sup></a><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="core-body-ref-r19-2" href-manipulated="true" aria-label="Reference 19" data-to-manipulate="false">19</a> Scores range from 0 to 11, with a score of 0 to 3 indicating low risk, a score of 4 or 5 indicating intermediate risk, and a score of 6 or higher indicating high risk. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was determined by the investigators.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers indicating greater disability. A score of 0 indicates that the patient is fully active and able to carry on all predisease performance without restriction, a score of 1 that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, and a score of 2 that the patient is ambulatory and capable of all self-care but is unable to carry out any work activities. Three patients in the placebo group had an ECOG performance-status score of 2 (which was outside the protocol specification). In one case, there was a randomization error and the patient was not treated in the trial. Two patients had a score of 1 at randomization but had a score of 2 on day 1 of the first cycle (baseline).</div></div></div></figcaption><figcaption><div class="caption">Characteristics of the Patients at Baseline (Intention-to-Treat Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2201817/asset/3064beda-1048-42cf-9e78-ed37027f229b/assets/images/large/nejmoa2201817_t2.jpg" height="3438" width="1548" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">System Organ Class and Preferred Term</th><th class="xxxx-borders" colspan="2"><span>Ibrutinib Group<br>(N=259)</span></th><th class="xxxx-borders" colspan="2"><span>Placebo Group<br>(N=260)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3 or 4</th></tr><tr class="head3" data-type="row head3"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">259 (100)</td><td class="xxxx-borders shading">211 (81.5)</td><td class="xxxx-borders shading">257 (98.8)</td><td class="xxxx-borders shading">201 (77.3)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Infection or infestation</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">87 (33.6)</td><td class="xxxx-borders shading">52 (20.1)</td><td class="xxxx-borders shading">61 (23.5)</td><td class="xxxx-borders shading">37 (14.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">71 (27.4)</td><td class="xxxx-borders">4 (1.5)</td><td class="xxxx-borders">68 (26.2)</td><td class="xxxx-borders">4 (1.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Bronchitis</td><td class="xxxx-borders shading">38 (14.7)</td><td class="xxxx-borders shading">6 (2.3)</td><td class="xxxx-borders shading">38 (14.6)</td><td class="xxxx-borders shading">6 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders">38 (14.7)</td><td class="xxxx-borders">11 (4.2)</td><td class="xxxx-borders">33 (12.7)</td><td class="xxxx-borders">6 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Sinusitis</td><td class="xxxx-borders shading">28 (10.8)</td><td class="xxxx-borders shading">2 (0.8)</td><td class="xxxx-borders shading">34 (13.1)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Conjunctivitis</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">24 (9.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">28 (10.8)</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Herpes zoster infection</td><td class="xxxx-borders">15 (5.8)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">28 (10.8)</td><td class="xxxx-borders">10 (3.8)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Gastrointestinal disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Diarrhea</td><td class="xxxx-borders">120 (46.3)</td><td class="xxxx-borders">18 (6.9)</td><td class="xxxx-borders">96 (36.9)</td><td class="xxxx-borders">10 (3.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">107 (41.3)</td><td class="xxxx-borders shading">6 (2.3)</td><td class="xxxx-borders shading">107 (41.2)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Vomiting</td><td class="xxxx-borders">58 (22.4)</td><td class="xxxx-borders">7 (2.7)</td><td class="xxxx-borders">48 (18.5)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">51 (19.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">68 (26.2)</td><td class="xxxx-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Abdominal pain</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxx-borders">30 (11.5)</td><td class="xxxx-borders">2 (0.8)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">General disorder or administration-site condition</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Pyrexia</td><td class="xxxx-borders">95 (36.7)</td><td class="xxxx-borders">5 (1.9)</td><td class="xxxx-borders">83 (31.9)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">79 (30.5)</td><td class="xxxx-borders shading">8 (3.1)</td><td class="xxxx-borders shading">77 (29.6)</td><td class="xxxx-borders shading">6 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Peripheral edema</td><td class="xxxx-borders">51 (19.7)</td><td class="xxxx-borders">3 (1.2)</td><td class="xxxx-borders">42 (16.2)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">30 (11.6)</td><td class="xxxx-borders shading">2 (0.8)</td><td class="xxxx-borders shading">25 (9.6)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Chills</td><td class="xxxx-borders">18 (6.9)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">39 (15.0)</td><td class="xxxx-borders">1 (0.4)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Blood or lymphatic system disorder<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">133 (51.4)</td><td class="xxxx-borders">122 (47.1)</td><td class="xxxx-borders">136 (52.3)</td><td class="xxxx-borders">125 (48.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">87 (33.6)</td><td class="xxxx-borders shading">40 (15.4)</td><td class="xxxx-borders shading">64 (24.6)</td><td class="xxxx-borders shading">23 (8.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Thrombocytopenia</td><td class="xxxx-borders">93 (35.9)</td><td class="xxxx-borders">33 (12.7)</td><td class="xxxx-borders">69 (26.5)</td><td class="xxxx-borders">34 (13.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Leukopenia</td><td class="xxxx-borders shading">47 (18.1)</td><td class="xxxx-borders shading">26 (10.0)</td><td class="xxxx-borders shading">44 (16.9)</td><td class="xxxx-borders shading">29 (11.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Lymphopenia</td><td class="xxxx-borders">47 (18.1)</td><td class="xxxx-borders">42 (16.2)</td><td class="xxxx-borders">35 (13.5)</td><td class="xxxx-borders">31 (11.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Skin or subcutaneous tissue disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Rash</td><td class="xxxx-borders">98 (37.8)</td><td class="xxxx-borders">31 (12.0)</td><td class="xxxx-borders">57 (21.9)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Pruritus</td><td class="xxxx-borders shading">46 (17.8)</td><td class="xxxx-borders shading">6 (2.3)</td><td class="xxxx-borders shading">56 (21.5)</td><td class="xxxx-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Maculopapular rash</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">12 (4.6)</td><td class="xxxx-borders">10 (3.8)</td><td class="xxxx-borders">3 (1.2)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Respiratory, thoracic, or mediastinal disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Cough</td><td class="xxxx-borders">77 (29.7)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">85 (32.7)</td><td class="xxxx-borders">2 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Epistaxis</td><td class="xxxx-borders shading">31 (12.0)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">12 (4.6)</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Dyspnea</td><td class="xxxx-borders">26 (10.0)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">46 (17.7)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02 shading">Metabolism or nutrition disorder</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders">56 (21.6)</td><td class="xxxx-borders">4 (1.5)</td><td class="xxxx-borders">36 (13.8)</td><td class="xxxx-borders">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders shading">39 (15.1)</td><td class="xxxx-borders shading">19 (7.3)</td><td class="xxxx-borders shading">31 (11.9)</td><td class="xxxx-borders shading">14 (5.4)</td></tr><tr data-type="row"><td class="xxxx-borders hanging02">Musculoskeletal or connective-tissue disorder</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Arthralgia</td><td class="xxxx-borders shading">45 (17.4)</td><td class="xxxx-borders shading">3 (1.2)</td><td class="xxxx-borders shading">44 (16.9)</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Back pain</td><td class="xxxx-borders">36 (13.9)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">37 (14.2)</td><td class="xxxx-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Myalgia</td><td class="xxxx-borders shading">31 (12.0)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">30 (11.5)</td><td class="xxxx-borders shading">3 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Nervous system disorder: headache</td><td class="xxxx-borders">33 (12.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">40 (15.4)</td><td class="xxxx-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Vascular disorder: hypertension</td><td class="xxxx-borders shading">35 (13.5)</td><td class="xxxx-borders shading">22 (8.5)</td><td class="xxxx-borders shading">29 (11.2)</td><td class="xxxx-borders shading">15 (5.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Injury, poisoning, or procedural complication: infusion-related reaction</td><td class="xxxx-borders">21 (8.1)</td><td class="xxxx-borders">2 (0.8)</td><td class="xxxx-borders">30 (11.5)</td><td class="xxxx-borders">5 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Cardiac disorder: atrial fibrillation</td><td class="xxxx-borders shading">36 (13.9)</td><td class="xxxx-borders shading">10 (3.9)</td><td class="xxxx-borders shading">17 (6.5)</td><td class="xxxx-borders shading">2 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Psychiatric disorder: insomnia</td><td class="xxxx-borders">29 (11.2)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">28 (10.8)</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Investigations: decreased weight</td><td class="xxxx-borders shading">26 (10.0)</td><td class="xxxx-borders shading">3 (1.2)</td><td class="xxxx-borders shading">20 (7.7)</td><td class="xxxx-borders shading">1 (0.4)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">An adverse event during treatment was defined as any event that occurred after the first dose of ibrutinib or placebo, through the treatment phase, or during the 30 days after the last dose of ibrutinib or placebo or until subsequent anticancer therapy, whichever occurred first; or as any event that was considered by the investigators to be related to ibrutinib or placebo regardless of the start date of the event; or as any event that was present at baseline but that worsened in severity or was subsequently considered by the investigator to be related to ibrutinib or placebo. The safety population included all the patients who received at least one dose of ibrutinib or placebo.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Preferred terms that were reported by the investigators were combined as follows: neutropenia (“neutropenia” and “neutrophil count decreased”), anemia (“anemia” and “hemoglobin decreased”), thrombocytopenia (“thrombocytopenia” and “platelet count decreased”), leukopenia (“leukopenia” and “white-cell count decreased’), and lymphopenia (“lymphopenia” and “lymphocyte count decreased”).</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events during Treatment That Occurred in at Least 10% of the Patients in Either Group (Safety Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2201817/asset/c239e748-d800-44ee-a939-565ded8e29cd/assets/images/large/nejmoa2201817_t3.jpg" height="2039" width="1136" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Cause</th><th class="txxx-borders">Ibrutinib Group<br>(N=261)</th><th class="txxr-borders">Placebo Group<br>(N=262)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Adverse event during treatment — no. (%)</td><td class="xxxx-borders shading">28 (10.7)</td><td class="xxxr-borders shading">16 (6.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Infection or infestation, excluding Covid-19 — no.<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">9</td><td class="xxxr-borders">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Covid-19–related event — no.</td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Unknown cause — no.</td><td class="xxxx-borders">3</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Cardiac disorder — no.<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">3</td><td class="xxxr-borders shading">5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Sudden death — no.</td><td class="xxxx-borders">2</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Multiple organ dysfunction syndrome — no.</td><td class="xxxx-borders shading">2</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Respiratory disorder — no.</td><td class="xxxx-borders">1</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">General physical health deterioration — no.</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Traumatic intracranial hemorrhage — no.</td><td class="xxxx-borders">1</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Tumor lysis syndrome — no.</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Cancer — no.<a href="#core-t3fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">1</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Ischemic stroke — no.</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Hemorrhagic stroke — no.</td><td class="xbxx-borders">0</td><td class="xbxr-borders">1</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">An adverse event during treatment was defined as any event that occurred after the first dose of ibrutinib or placebo, through the treatment phase, or during the 30 days after the last dose of ibrutinib or placebo or until subsequent anticancer therapy, whichever occurred first; or as any event that was considered by the investigator to be related to ibrutinib or placebo regardless of the start date of the event; or as any event that was present at baseline but that worsened in severity or was subsequently considered by the investigator to be related to ibrutinib or placebo. Covid-19 denotes coronavirus disease 2019.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Grade 5 events of infections and infestations in the ibrutinib group included pneumonia (in two patients) and bronchopulmonary aspergillosis, hepatitis B virus infection, nosocomial infection, <i>Pneumocystis jirovecii</i> pneumonia, fungal pneumonia, viral pneumonia, and sepsis (in one patient each); events in the placebo group included pneumonia, pulmonary sepsis, sepsis, septic shock, and pseudomembranous colitis (in one patient each).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Grade 5 events of cardiac disorders in the ibrutinib group included cardiac arrest (in two patients) and cardiorespiratory arrest (in one); events in the placebo group included cardiopulmonary failure (in two patients) and cardiac arrest and myocardial infarction (in one patient each).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Grade 5 events of cancer occurred in one patient in the ibrutinib group (acute myeloid leukemia) and in two in the placebo group (acute myeloid leukemia and myelodysplastic syndrome).</div></div></div></figcaption></a><figcaption><div class="caption">Causes of Death Due to Adverse Events during Treatment.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2201817_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2201817</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. <em>Am J Hematol</em> 2019;94:710-725.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ajh.25487" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30963600/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000467587800024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mantle+cell+lymphoma%3A+2019+update+on+the+diagnosis%2C+pathogenesis%2C+prognostication%2C+and+management.&amp;publication_year=2019&amp;journal=Am+J+Hematol&amp;pages=710-725&amp;doi=10.1002%2Fajh.25487&amp;pmid=30963600" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <em>Lancet</em> 2016;388:565-575.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00739-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27313086/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380756600029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Addition+of+high-dose+cytarabine+to+immunochemotherapy+before+autologous+stem-cell+transplantation+in+patients+aged+65+years+or+younger+with+mantle+cell+lymphoma+%28MCL+Younger%29%3A+a+randomised%2C+open-label%2C+phase+3+trial+of+the+European+Mantle+Cell+Lymphoma+Network.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=565-575&amp;doi=10.1016%2FS0140-6736%2816%2900739-X&amp;pmid=27313086" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. <em>N Engl J Med</em> 2017;377:1250-1260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2201817&amp;key=10.1056%2FNEJMoa1701769&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28953447/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411838100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+after+autologous+stem-cell+transplantation+in+mantle-cell+lymphoma.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1250-1260&amp;doi=10.1056%2FNEJMoa1701769&amp;pmid=28953447" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Robak T, Smolewski P, Robak P, Dreyling M. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. <em>Leuk Lymphoma</em> 2019;60:2622-2634.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/10428194.2019.1605511" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31018735/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000470604700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mantle+cell+lymphoma%3A+therapeutic+options+in+transplant-ineligible+patients.&amp;publication_year=2019&amp;journal=Leuk+Lymphoma&amp;pages=2622-2634&amp;doi=10.1080%2F10428194.2019.1605511&amp;pmid=31018735" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Monga N, Tam C, Garside J, et al. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review. <em>Crit Rev Oncol Hematol</em> 2021;158:103212-103212.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.critrevonc.2020.103212" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33383209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000624896000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+efficacy+and+safety+of+first-line+treatments+in+patients+with+mantle+cell+lymphoma%3A+a+systematic+literature+review.&amp;publication_year=2021&amp;journal=Crit+Rev+Oncol+Hematol&amp;pages=103212-103212&amp;doi=10.1016%2Fj.critrevonc.2020.103212&amp;pmid=33383209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. <em>Br J Haematol</em> 2018;182:46-62.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.15283" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29767454/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436244700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guideline+for+the+management+of+mantle+cell+lymphoma.&amp;publication_year=2018&amp;journal=Br+J+Haematol&amp;pages=46-62&amp;doi=10.1111%2Fbjh.15283&amp;pmid=29767454" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <em>Ann Oncol</em> 2017;28:Suppl_4:iv62-iv71.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdx223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28881919/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405408400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Newly+diagnosed+and+relapsed+mantle+cell+lymphoma%3A+ESMO+clinical+practice+guidelines+for+diagnosis%2C+treatment+and+follow-up.&amp;publication_year=2017&amp;journal=Ann+Oncol&amp;pages=iv62-iv71&amp;doi=10.1093%2Fannonc%2Fmdx223&amp;pmid=28881919" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">National Comprehensive Cancer Network (NCCN). <em>Clinical practice guidelines in oncology: B-cell lymphomas, version 5</em>. 2021 (<a href="https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1480">https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1480</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+practice+guidelines+in+oncology%3A+B-cell+lymphomas%2C+version+5&amp;publication_year=2021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Martin P, Wang M, Kumar A, et al. Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice. <em>J Clin Oncol</em> 2021;39:Suppl:7504-7504. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2021.39.15_suppl.7504" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000708120604101" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Real-world+%28RW%29+treatment+%28tx%29+patterns+and+outcomes+of+3%2C455+previously+untreated+mantle+cell+lymphoma+%28MCL%29+patients+%28pts%29+in+U.S.+routine+clinical+practice.&amp;publication_year=2021&amp;journal=J+Clin+Oncol&amp;pages=7504-7504&amp;doi=10.1200%2FJCO.2021.39.15_suppl.7504" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] regimens for mantle-cell lymphoma, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Two independent observational studies </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] survival was 1.5 to 3.5 years. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. <em>Lancet</em> 2013;381:1203-1210.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(12)61763-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23433739/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000317350100030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bendamustine+plus+rituximab+versus+CHOP+plus+rituximab+as+first-line+treatment+for+patients+with+indolent+and+mantle-cell+lymphomas%3A+an+open-label%2C+multicentre%2C+randomised%2C+phase+3+non-inferiority+trial.&amp;publication_year=2013&amp;journal=Lancet&amp;pages=1203-1210&amp;doi=10.1016%2FS0140-6736%2812%2961763-2&amp;pmid=23433739" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] than with R-CHOP (35.4 vs. 22.1 months) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and a better safety profile. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] survival was 1.5 to 3.5 years. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] ibrutinib, bendamustine, and rituximab. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. <em>J Clin Oncol</em> 2019;37:984-991.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.00605" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30811293/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000466717700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+treatment+of+patients+with+indolent+non-Hodgkin+lymphoma+or+mantle-cell+lymphoma+with+bendamustine+plus+rituximab+versus+R-CHOP+or+R-CVP%3A+results+of+the+BRIGHT+5-year+follow-up+study.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=984-991&amp;doi=10.1200%2FJCO.18.00605&amp;pmid=30811293" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Hill BT, Switchenko JM, Martin P, et al. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab (BR). <em>Hematol Oncol</em> 2019;37:Suppl 2:405-407.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hon.75_2631" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Maintenance+rituximab+is+associated+with+improved+overall+survival+in+mantle+cell+lymphoma+patients+responding+to+induction+therapy+with+bendamustine+%2B+rituximab+%28BR%29.&amp;publication_year=2019&amp;journal=Hematol+Oncol&amp;pages=405-407&amp;doi=10.1002%2Fhon.75_2631" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). <em>J Clin Oncol</em> 2016;34:Suppl:7503-7503. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.34.15_suppl.7503" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404711505017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two+years+rituximab+maintenance+vs.+observation+after+first-line+treatment+with+bendamustine+plus+rituximab+%28B-R%29+in+patients+with+mantle+cell+lymphoma%3A+first+results+of+a+prospective%2C+randomized%2C+multicenter+phase+II+study+%28a+subgroup+study+of+the+StiL+NHL7-2008+MAINTAIN+trial%29.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=7503-7503&amp;doi=10.1200%2FJCO.2016.34.15_suppl.7503" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial. <em>J Clin Oncol</em> 2020;38:248-256.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.01294" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31804876/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000508197300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Treatment+of+older+patients+with+mantle+cell+lymphoma+%28MCL%29%3A+long-term+follow-up+of+the+randomized+European+MCL+Elderly+trial.&amp;publication_year=2020&amp;journal=J+Clin+Oncol&amp;pages=248-256&amp;doi=10.1200%2FJCO.19.01294&amp;pmid=31804876" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <em>N Engl J Med</em> 2013;369:507-516.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2201817&amp;key=10.1056%2FNEJMoa1306220&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23782157/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000322842000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+BTK+with+ibrutinib+in+relapsed+or+refractory+mantle-cell+lymphoma.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=507-516&amp;doi=10.1056%2FNEJMoa1306220&amp;pmid=23782157" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <em>Leukemia</em> 2018;32:1799-1803.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0023-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29572505/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000441284000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ibrutinib+versus+temsirolimus%3A+3-year+follow-up+of+patients+with+previously+treated+mantle+cell+lymphoma+from+the+phase+3%2C+international%2C+randomized%2C+open-label+RAY+study.&amp;publication_year=2018&amp;journal=Leukemia&amp;pages=1799-1803&amp;doi=10.1038%2Fs41375-018-0023-2&amp;pmid=29572505" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] when it is used at first relapse. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] ibrutinib, bendamustine, and rituximab. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Rule S, Dreyling MH, Goy A, et al. Long-term outcomes with ibrutinib versus the prior regimen: a pooled analysis in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. <em>Blood</em> 2019;134:Suppl 1:1538-1538. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2019-124691" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000577160402091" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+outcomes+with+ibrutinib+versus+the+prior+regimen%3A+a+pooled+analysis+in+relapsed%2Frefractory+%28R%2FR%29+mantle+cell+lymphoma+%28MCL%29+with+up+to+7.5+years+of+extended+follow-up.&amp;publication_year=2019&amp;journal=Blood&amp;pages=1538-1538&amp;doi=10.1182%2Fblood-2019-124691" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Maddocks K, Christian B, Jaglowski S, et al. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. <em>Blood</em> 2015;125:242-248.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2014-08-597914" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25355819/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350810200013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+1%2F1b+study+of+rituximab%2C+bendamustine%2C+and+ibrutinib+in+patients+with+untreated+and+relapsed%2Frefractory+non-Hodgkin+lymphoma.&amp;publication_year=2015&amp;journal=Blood&amp;pages=242-248&amp;doi=10.1182%2Fblood-2014-08-597914&amp;pmid=25355819" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <em>Blood</em> 2008;111:558-565.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2007-06-095331" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17962512/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000252458700025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+new+prognostic+index+%28MIPI%29+for+patients+with+advanced-stage+mantle+cell+lymphoma.&amp;publication_year=2008&amp;journal=Blood&amp;pages=558-565&amp;doi=10.1182%2Fblood-2007-06-095331&amp;pmid=17962512" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] risk [4 or 5], or high risk [6 to 11]). </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#t1" role="menuitem" data-target="#fv-body-ref-r19-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] score (low vs. intermediate vs. high risk). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. <em>J Clin Oncol</em> 2007;25:579-586.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2006.09.2403" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17242396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000244176000018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Revised+response+criteria+for+malignant+lymphoma.&amp;publication_year=2007&amp;journal=J+Clin+Oncol&amp;pages=579-586&amp;doi=10.1200%2FJCO.2006.09.2403&amp;pmid=17242396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Hlubocky FJ, Webster K, Cashy J, Beaumont J, Cella D. The development and validation of a measure of health-related quality of life for non-Hodgkin’s lymphoma: the Functional Assessment of Cancer Therapy — Lymphoma (FACT-Lym). <em>Lymphoma</em> 2013;1-9 (<a href="https://www.hindawi.com/journals/lymph/2013/147176/">https://www.hindawi.com/journals/lymph/2013/147176/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1155/2013/147176" target="_blank">Crossref</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+development+and+validation+of+a+measure+of+health-related+quality+of+life+for+non-Hodgkin%E2%80%99s+lymphoma%3A+the+Functional+Assessment+of+Cancer+Therapy+%E2%80%94+Lymphoma+%28FACT-Lym%29.&amp;publication_year=2013&amp;journal=Lymphoma&amp;pages=1-9&amp;doi=10.1155%2F2013%2F147176" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. <em>N Engl J Med</em> 2015;372:944-953.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2201817&amp;key=10.1056%2FNEJMoa1412096&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25738670/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000350304500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bortezomib-based+therapy+for+newly+diagnosed+mantle-cell+lymphoma.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=944-953&amp;doi=10.1056%2FNEJMoa1412096&amp;pmid=25738670" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. <em>Lancet Oncol</em> 2018;19:1449-1458.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(18)30685-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30348538/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000449100300042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Frontline+bortezomib%2C+rituximab%2C+cyclophosphamide%2C+doxorubicin%2C+and+prednisone+%28VR-CAP%29+versus+rituximab%2C+cyclophosphamide%2C+doxorubicin%2C+vincristine%2C+and+prednisone+%28R-CHOP%29+in+transplantation-ineligible+patients+with+newly+diagnosed+mantle+cell+lymphoma%3A+final+overall+survival+results+of+a+randomised%2C+open-label%2C+phase+3+study.&amp;publication_year=2018&amp;journal=Lancet+Oncol&amp;pages=1449-1458&amp;doi=10.1016%2FS1470-2045%2818%2930685-5&amp;pmid=30348538" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Albertsson-Lindblad A, Palsdottir T, Smedby KE, Weibull CE, Glimelius I, Jerkeman M. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen — a real world study on patients diagnosed in Sweden 2007–2017. <em>Haematologica</em> 2022;107:740-743.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3324/haematol.2021.279037" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34788983/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000811240400054" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Survival+in+mantle+cell+lymphoma+after+frontline+treatment+with+R-bendamustine%2C+R-CHOP+and+the+Nordic+MCL2+regimen+%E2%80%94+a+real+world+study+on+patients+diagnosed+in+Sweden+2007%E2%80%932017.&amp;publication_year=2022&amp;journal=Haematologica&amp;pages=740-743&amp;doi=10.3324%2Fhaematol.2021.279037&amp;pmid=34788983" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 21, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2209904" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Treatment of Mantle-Cell Lymphoma</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Rockport, Maine</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885457/gastroenterology-physician-rockport-maine/?query=fjwp&amp;rid=1000">Gastroenterology Physician - Rockport, Maine</a></div></div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/785762/obgyn-maternal-fetal-medicine-new-york-ny-/?query=fjwp&amp;rid=3059">OBGYN - Maternal Fetal Medicine - (New York, NY) </a></div></div><div class="nejm-widget_item"><div><span> Valhalla, New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882981/radiologist/?query=fjwf&amp;rid=22466">Radiologist</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891680/reliant-medical-group-hematologist-oncologist-full-time-worcester-ma/?query=fjwf&amp;rid=220874">Reliant Medical Group - Hematologist/Oncologist - Full Time - Worcester, MA</a></div></div><div class="nejm-widget_item"><div><span> Florida</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886310/gastroenterology-1m-proven-income-2-yr-partnership-track-orlando-suburbs/?query=fjwf&amp;rid=5263">Gastroenterology | $1M+ Proven Income | 2 Yr Partnership Track | Orlando Suburbs</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885285/heart-failure-specialist-long-island-new-york/?query=fjwp&amp;rid=6262">Heart Failure Specialist Long Island, New York</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2201817&amp;pubId=41283961&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6dab1c267af0b-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6dab1c267af0b-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6dab1c267af0b-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$926521350$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$926521350$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$926521350$--></div></div><div class="mlt-body"><!--?lit$926521350$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$926521350$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$926521350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$926521350$-->Jun 30, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2202672?query=recirc_Semantic" target="_self">Mantle-Cell Lymphoma</a></div><div class="mlt-article-authors"><!--?lit$926521350$-->J.O. Armitage and D.L. Longo</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$926521350$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$926521350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$926521350$-->Jun 20, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401532?query=recirc_Semantic" target="_self">Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma</a></div><div class="mlt-article-authors"><!--?lit$926521350$-->C. Melani and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$926521350$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$926521350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$926521350$-->Jan 26, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211582?query=recirc_Semantic" target="_self">Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia</a></div><div class="mlt-article-authors"><!--?lit$926521350$-->J.R. Brown and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/editorial?query=recirc_Semantic" target="_self"><!--?lit$926521350$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$926521350$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$926521350$-->May 13, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDe2200093?query=recirc_Semantic" target="_self">Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment</a></div><div class="mlt-article-authors"><!--?lit$926521350$-->W.G. Wierda</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$926521350$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$926521350$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$926521350$-->Mar 04, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra2027612?query=recirc_Semantic" target="_self">Diffuse Large B-Cell Lymphoma</a></div><div class="mlt-article-authors"><!--?lit$926521350$-->L.H. Sehn and G. Salles</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2201817?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2201817" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2201817.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2201817"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2202028" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMra2202672" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Mantle-Cell Lymphoma</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f0.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/886df89e-7380-447d-a885-20a73385c3b1/assets/images/large/nejmoa2201817_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f1.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/bb8ba227-09e7-4808-a440-ea40502fbf61/assets/images/large/nejmoa2201817_f1.jpg" height="2809" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Progression-free Survival and Overall Survival (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">The intention-to-treat population included all the patients who underwent randomization. Panel A shows the Kaplan–Meier curves for progression-free survival, which was assessed by the investigators according to the Revised Response Criteria for Malignant Lymphoma. The median progression-free survival was 80.6 months (95% CI, 61.9 to not evaluable) with ibrutinib plus bendamustine and rituximab, as compared with 52.9 months (95% CI, 43.7 to 71.0) with placebo plus bendamustine and rituximab. The significance boundary for superiority was a P value of less than 0.023. Panel B shows the Kaplan–Meier curves for overall survival at a median follow-up of 84.7 months (range, 0.1 to 97.5). There was no significant between-group difference in overall survival. As of the data-cutoff date, the median overall survival had not been reached in either group. Symbols in both panels indicate censored data.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2201817_f2.jpg"><img src="/cms/10.1056/NEJMoa2201817/asset/fb5ae19a-5497-47cf-acc3-462969d3ad6d/assets/images/large/nejmoa2201817_f2.jpg" height="1977" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Subgroup Analysis of Progression-free Survival (Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Progression-free survival was assessed by the investigators according to the Revised Response Criteria for Malignant Lymphoma. Race was determined by the investigators. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher numbers indicating greater disability. A score of 0 indicates that the patient is fully active and able to carry on all predisease performance without restriction, a score of 1 that the patient is restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, and a score of 2 that the patient is ambulatory and capable of all self-care but is unable to carry out any work activities. Scores on the simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) range from 0 to 11, with a score of 0 to 3 indicating low risk, a score of 4 or 5 indicating intermediate risk, and a score of 6 or higher indicating high risk. Tumor bulk was assessed on the largest diameter.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline (Intention-to-Treat Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events during Treatment That Occurred in at Least 10% of the Patients in Either Group (Safety Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Causes of Death Due to Adverse Events during Treatment.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/26" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 26</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 30, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2202028" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Gállego Pérez-Larraya and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 30, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2202707" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Restriction of Intravenous Fluid in ICU Patients with Septic Shock</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.S. Meyhoff and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 30, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2202672" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Mantle-Cell Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.O. Armitage and D.L. Longo</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2201817%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2201817&amp;pubId=41283961&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2201817%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2201817&amp;pubId=41283961&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id00657817506934063" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6dab1c267af0b-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6dab1c267af0b-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6dab1c267af0b-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6dab1c267af0b-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6dab1c267af0b-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6dab1c267af0b-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6dab1c267af0b-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6dab1c267af0b-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6dab1c267af0b-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6dab1c267af0b-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6dab1a8ceaf0b',t:'MTc0OTUzNzM4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6dab1a8ceaf0b&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><ccm-yigbgyqhhxvw></ccm-yigbgyqhhxvw><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2201817?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><iframe name="captureIFrame_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-transactionid="97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" id="captureIFrame_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" target="captureIFrame_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="capture_screen"><input id="capture_signIn_js_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="js_version"><input id="capture_signIn_transactionId_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" type="hidden" class="capture_transactionId_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="capture_transactionId"><input id="capture_signIn_form_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="form"><input id="capture_signIn_flow_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="flow"><input id="capture_signIn_client_id_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="client_id"><input id="capture_signIn_redirect_uri_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="redirect_uri"><input id="capture_signIn_response_type_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="response_type"><input id="capture_signIn_flow_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="flow_version"><input id="capture_signIn_settings_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="settings_version"><input id="capture_signIn_locale_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="locale"><input id="capture_signIn_recaptcha_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_97kr7i71ssfvebneisw02week8ugq6vm4jbm4rwk" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>